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ABSTRACT 
 
Proangiogenic gene therapy, with viral and non-viral vectors, has been shown to be highly 
efficient in several animal models. These results have encouraged investigators to proceed 
to treatment of patients with these new therapies in Phase I to III clinical trials. However, 
promising results of pre-clinical experiments have not fully translated into clinical success 
and as such improvements in the vectors and methods are under investigation. In addition, 
new target diseases are being actively searched for where gene therapy induced 
angiogenesis might be beneficial. The aims of this study were (1) to test whether a novel 
gamma secretase inhibitor (Compound X, CX) or baculoviruses are useful in improving 
skeletal muscle gene therapy efficacy and (2) to investigate the transduction efficiency and 
safety aspects, in terms of fetal survival, of adenovirus-based gene therapy, when it is 
injected into the uterine artery during pregnancy. 
In this study it was found that, CX efficiently improved vascular sprouting in cell 
cultures and in a mouse eye model. However, when CX was combined with adenoviral 
vascular endothelial growth factor (VEGF)-A gene transfer, in rabbit skeletal muscle, it 
actually disrupted the vessel endothelial cell layer integrity. In addition, there was a similar 
endothelial cell disruption detected in the liver following the combination therapy. 
Capillary growth was evident in the rabbit skeletal muscles 6 days after the baculovirus 
mediated VEGF-DΔNΔC gene transfer. When baculovirus was used as a vector to carry 
VEGF-DΔNΔC gene a significant improvement was seen in different cell lines after addition of 
VSV-G and WPRE into the vector. In the last study of the dissertation, three different genes 
were used to test the safety of adenoviral gene transfer to the uterine artery: thymidine 
kinase (Tk, with Ganciclovir), VEGF-DΔNΔC and LacZ. Adenovirus did not influence fetal 
survival when injected into the uterine artery at the end of the second trimester of the 
pregnancy. The transgene was found with PCR in 9 % of the offspring livers but no 
integration of the transgene was seen. In addition, qPCR analysis did not reveal any 
expression of the transgene in the fetal livers. 
In conclusion, we found that the safety profiles of CX or baculoviral gene therapy need 
to be further improved to become suitable for use in future in vivo studies, at least as pro-
angiogenic therapies. In addition, the safety profile of adenoviral gene therapy was such 
that further studies are justified. Thus, new vectors and molecules which are highly 
efficient in cell culture and in rodent models should be evaluated for potency and safety 
also in larger animal models, such as rabbits or pigs, which better resemble human 
pharmacological properties before entering clinical trials. 
 
National Library of Medicine Classification: QU 107, QU 560, WE 500, WG 500 
Medical Subject Headings: Genetic Therapy; Angiogenesis Inducing Agents; Blood Vessels/growth & 
development; Muscle, Skeletal; Uterine Artery; Amyloid Precursor Protein Secretases/antagonists & 
inhibitors; Adenoviridae; Vascular Endothelial Growth Factor A; Baculoviridae; Vascular Endothelial Growth 
Factor D; Cells, Cultured; Endothelial Cells/drug effects; Disease Models, Animal; Safety 
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TIIVISTELMÄ 
 
Verisuonten kasvua edistävä geeniterapia viraalisia ja ei-viraalisia vektoreita käyttäen on 
todistettu hyvin tehokkaaksi useissa eri eläinmalleissa. Nämä tulokset ovat rohkaisseet 
tutkijoita hoitamaan potilaita näillä uusilla terapiamuodoilla kliinisissä faasi I-III kokeissa. 
Lupaavat tulokset prekliinisissä kokeissa eivät kuitenkaan ole suoraan sovellettavissa 
kliiniseen lääketieteeseen ja vektoreita sekä menetelmiä kehitetäänkin edelleen. Lisäksi 
uusia hoitokohteita, joissa lisääntyneestä verenvirtauksesta voisi olla hyötyä, etsitään 
aktiivisesti. Tämän tutkimuksen tarkoituksena oli testata (1) voisivatko joko uusi 
gammasekretaasi inhibiittori (Compound X) tai bakulovirus olla käyttökelpoisia 
luurankolihaksen geeniterapian tehostajia ja (2) onko adenovirus tehokas ja turvallinen 
sikiön kehittymiselle jos se injektoidaan kohtuvaltimoon raskauden aikana. 
Vaikka Compound X vaikutti tehokkaalta soluviljelmässä ja hiiren silmämallissa, 
verisuonen endoteelikasvutekijä (VEGF) A:lla aiheutetun kapillaarisuonten laajentumisen 
yhteydessä kanin luurankolihaksessa se itse asiassa aiheutti häiriötilan endoteelisolukon 
eheyteen. Samanlainen endoteelisolukon häiriötila oli havaittavissa myös maksassa. Kun 
bakulovirusta käytettiin vektorina kuljettamaan VEGF-DΔNΔC siirtogeeniä, merkittävä 
parannus tehossa nähtiin eri solulinjoilla kun vektoriin lisättiin VSV-G ja Wpre –elementit. 
Lisäksi kapillaarien laajeneminen oli ilmeinen 6 päivää kanin luurankolihakseen tehdyn 
geeninsiirron jälkeen. Kolmea erilaista geeniä käytettiin testauksessa, kun haluttiin tutkia 
adenovirusvälitteisen geeninsiirron turvallisuutta kohtuvaltimoon; tymidiinikinaasi 
(Gancicloviirin kanssa), VEGF-DΔNΔC ja LacZ. Adenoviruksen injektoimisella 
kohtuvaltimoon raskauden toisen kolmanneksen lopulla ei näyttäisi olevan vaikutusta 
sikiön selviytymiseen. Siirtogeeni löytyi PCR-menetelmällä 9 %:ssa jälkeläisten maksoista, 
mutta merkkejä siirtogeenin integroitumisesta perimään ei havaittu. Lisäksi qPCR-
menetelmällä ei havaittu siirtogeenin ilmentymistä sikiöiden maksassa. 
Yhteenvetona voidaan todeta, että Compound X:n ja bakuloviruksen 
turvallisuusprofiilia tulee vielä parantaa, ennen kuin niille voidaan suunnitella uusia 
angiogeneesiä lisääviä eläinkokeita. Adenovirusvälitteisen geeniterapian 
turvallisuusprofiili puolestaan oikeuttaa jatkokokeet. Näin ollen uudet vektorit ja 
molekyylit, jotka ovat hyvin tehokkaita soluviljelmissä ja pieneläinmalleissa (hiiri, rotta), 
tulisi ennen kliinisiä kokeita testata tehon ja turvallisuuden suhteen myös isoeläinmalleissa, 
kuten kanissa tai siassa, jotka farmakologisilta ominaisuuksiltaan ovat lähempänä ihmistä. 
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kasvutekijät; soluviljely; endoteeli; koe-eläimet; turvallisuus 
  
VIII 
 
 
 
 
  
IX 
 
 
Acknowledgements 
To my main supervisor Professor Seppo Ylä-Herttuala, I wish to thank you for all the 
opportunities you have given me. Firstly, the position you gave me as a technician over a 
decade ago, then the possibility to complete a master’s degree in parallel, and finally the 
opportunity to aim for the doctoral degree. I appreciate the faith and encouragement you 
have shown me during these years when a variety of projects have not been so successful. 
You did not show any frustration even when I came to your office with my third proposal 
of the dissertation outline. Docent Tuomas Rissanen, you were the driving force that 
initially gave me the idea to pursue this career. The hours and days spent in LAC facilities 
and in laboratory processing and analyzing samples woke up the researcher inside me. I 
also wish to express my deepest gratitude for the effort you have put in reviewing 
manuscripts and this dissertation. Docent Varpu Marjomäki and Docent Mikko Laukkanen, 
your critical thoughts and suggestions definitely made this dissertation better. PhD Nihay 
Laham-Karam, I wish to thank you for the diligent review of the language. 
To co-workers at both AIV Institute and Ark Therapeutics Oy, without you these years 
would not have been as exceptional as they were. Even though there were issues during the 
years that were rather depressing, you were the ones who made it worth coming back 
every morning. I would like to greatly acknowledge those who contributed to the articles in 
this dissertation, especially Sunnu and Lubo for the help on FGR model, Henna and 
Associate Professor Mats Hellström for the GSI study and Tiina and Professor Kari Airenne 
for the baculo study. Svetlana, I lack the words to describe the importance of your unselfish 
commitment to the research; no matter how minor or laborious the task, you were always 
happy to help. Former and present roommates; Diana, Emilia, Krista, Lubo, Pyry, Svetlana, 
Taina, Tiina and Tytteli, as well as Ann-Marie, Anssi, Hanna, Haritha, Jere, Jani, Minna, 
Mikko, Olli, Thomas and Vesa, I thank you for all the scientific and not-so-scientific debates 
we have had. Joonas, I value those numerous cups of coffee and discussions about various 
aspects of life we have had, and your professional attitude is well recognized. 
I have received a lot of invaluable help from many colleagues at AIVI and Ark. There are 
so many names I should raise, so do forgive me if anyone who deserves to be mentioned is 
missing. The “animal group” (Tuomas, Juha, Pärrä, Hanna, Johanna, Matias, Olli, Antti, 
Sunnu and Ella from the early days and all you who have joined in during the years) is 
praised for both the working attitude and the rather disturbed sense of humor. The same 
applies to the whole SYH group, it has been a privilege to work with you. 
Tiina, Sari, as well as Ark’s production and development teams are acknowledged for 
the adenoviruses; Tarja, Joonas and Jaana for the baculoviruses; Seija and Mervi for the 
histology; Anne, Anneli, Helena and Marja for the miscellaneous technical and secretarial 
help. I here give my deepest gratitude to any technician, secretery, student, undergraduate, 
PhD student, researcher, post-doc, senior scientist, docent, director or professor I have 
bothered with my endless queries for help or information. In addition, the truly skillful 
personnel in LAC, I thank you for all the effort and help during the experiments. 
  
X 
 
 
Mother, Maria, Markus and your families, I truly appreciate the support and relaxing 
times I have been able to spend with you. Kinsfolk and friends, our contacts have been 
becoming quite rare as years have gone by, but it really does not seem to matter once we 
eventually get in touch again. Kössi, let us keep our annual KalPa-Ässät tradition alive for 
years to come. 
Ronja, such a gloomy day doesn’t exist that your vivacity wouldn’t brighten up. 
 
 
 
 
Kuopio, December 2013 
 
 
 
 
Tommi 
 
 
 
 
 
 
 
 
 
 
This study has been supported by Ark Therapeutics Oy and grants from the Finnish 
Cultural Foundation, Sigrid Juselius Foundation and University of Eastern Finland. 
  
XI 
 
 
List of the original publications  
 
 
This dissertation is based on the following original publications:  
 
 
I Kalén M, Heikura T*, Karvinen H*, Nitzsche A, Weber H, Esser N, Ylä-Herttuala 
S and Hellström M. Gamma-Secretase Inhibitor Treatment Promotes VEGF-A-
Driven Blood Vessel Growth and Vascular Leakage but Disrupts Neovascular 
Perfusion. PLoS One 6(4). e18709, 2011. 
 
II Heikura T, Nieminen T, Roschier MM, Karvinen H, Mähönen AJ, Lesch HP, 
Rissanen TT, Laitinen OH, Airenne KJ* and Ylä-Herttuala S*. Baculovirus-
mediated VEGF-DΔNΔC Gene Transfer Induces Capillary Enlargement in Rabbit 
Skeletal Muscle. J Gene Med. 14(1). 35-43, 2012. 
 
III Laurema A, Riekkinen M, Heikura T, Vähäkangas E, Manninen H, Heinonen S 
and Ylä-Herttuala S. The Administration of an Adenoviral Thymidine Kinase 
Suicide Gene to the Uterine Artery of Rabbits Does Not Affect Fertility: A Safety 
Study of Pregnant and Nonpregnant Rabbits and Their Offspring. J Gene Med 
10(9). 1005-1011, 2008. 
 
 
 
 
* Authors with equal contribution 
Also unpublished data is presented. 
The publications were adapted with the permission of the copyright owners. 
 
  
XII 
 
 
  
XIII 
 
 
Contents 
1 Introduction ................................................................................................................................. 1 
2 Review of the literature ............................................................................................................. 3 
2.1 DISEASES AND DISORDERS FEASIBLE FOR ANGIOGENIC GENE THERAPY .... 3 
2.1.1 Peripheral and coronary arterial disease .................................................................. 3 
2.1.2 Fetal growth restriction ............................................................................................... 4 
2.2 ANGIOGENIC GENE THERAPY...................................................................................... 5 
2.2.1 Angiogenesis ................................................................................................................ 5 
2.2.2 Vascular endothelial growth factors ......................................................................... 6 
2.2.2.1 VEGFR-1 and its mechanisms of action ................................................................... 8 
2.2.2.2 VEGFR-2 and its mechanisms of action ................................................................... 9 
2.2.3 Notch signaling in angiogenesis .............................................................................. 10 
2.2.4 Gene therapy vectors ................................................................................................ 11 
2.2.4.1 Adenoviruses .......................................................................................................... 12 
2.2.4.2 Baculoviruses .......................................................................................................... 13 
2.2.4.3 Other viral and non-viral vectors ........................................................................... 14 
2.2.5 Regulatory guidelines for safety testing ................................................................. 15 
2.2.5.1 Non-clinical studies before clinical use .................................................................. 16 
2.2.5.2 Reproductive toxicity.............................................................................................. 17 
2.2.5.3 Germline transmission ........................................................................................... 17 
2.3 ANIMAL MODELS FOR PAD, FGR AND REPRODUCTIVE TOXICOLOGY ......... 18 
2.3.1 Peripheral arterial disease ........................................................................................ 18 
2.3.2 Fetal growth restriction and reproductive toxicology .......................................... 19 
2.4 ETHICAL ASPECTS OF GENE TRANSFER THERAPY .............................................. 19 
3 Aims of the study ...................................................................................................................... 21 
4 Materials and methods ............................................................................................................ 23 
4.1 VECTOR PRODUCTION AND TESTING ..................................................................... 23 
4.1.1 Adenoviruses (I, III) .................................................................................................. 23 
4.1.2 Baculoviruses (II) ....................................................................................................... 23 
4.2 IN VITRO TESTING OF GSI (I) ........................................................................................ 23 
4.3 ANIMAL MODELS (I-III) ................................................................................................. 23 
4.3.1 Mouse models for GSI testing (I) ............................................................................. 24 
4.3.2 Rabbit model for skeletal muscle gene transfer (I, II) ........................................... 24 
4.3.3 Rabbit model for reproductive toxicity testing (III, unpublished work) ........... 24 
4.4 ENZYME LINKED IMMUNOSORBENT ASSAY (II) ................................................... 25 
4.5 HISTOLOGY (I-III, UNPUBLISHED WORK) ................................................................ 26 
4.6 RT-PCR, PCR AND QPCR (III, UNPUBLISHED WORK) ............................................ 26 
4.7 SOUTHERN BLOTTING (III) ........................................................................................... 27 
4.8 STATISTICAL ANALYSES (I-II) ...................................................................................... 27 
5 Results and discussion............................................................................................................. 29 
5.1 EFFECT AND SAFETY OF COMPOUND X (I) ............................................................. 29 
5.2 EFFICACY AND SAFETY OF THE BACULOVIRAL GENE TRANSFER (II)........... 31 
5.3 ANIMAL MODEL FOR REPRODUCTIVE TOXICOLOGY (III, UNPUBLISHED 
      DATA) ................................................................................................................................. 33 
6 Conclusions ............................................................................................................................... 37 
References ..................................................................................................................................... 39 
   
 
XIV 
 
 
  
XV 
 
 
 
Abbreviations 
 
293T human embryonic kidney cell 
line with SV40 large T-
antigen 
aa amino acid 
AAV adeno-associated virus 
ABI ankle-brachial index 
AcMNPV Autographa californica multiple 
nucleopolyhedrovirus 
Ad adenovirus 
Akt protein kinase B 
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 1 Introduction 
Gene therapy has shown its potency in various preclinical models both in vitro and in vivo. 
However, in the Western World only one product has gained marketing authorization even 
though hundreds of clinical trials have been conducted in the last decades. In ischemic 
diseases, proangiogenic gene therapy has been widely studied using different growth 
factors and vectors. These trials have shown that these methods are very promising in pre-
clinical experiments. Many of them have already proceeded to clinical trials. Proangiogenic 
gene therapy has been proven safe and well tolerated in humans but the efficacy has not 
met the expectations set by the pre-clinical trials (Vuorio, Jauhiainen, and Ylä-Herttuala 
2012). 
The majority of proangiogenic clinical trials have been conducted with vectors that have 
transient transgene expression, such as plasmids and adenoviruses. It was shown in a 
transgenic mouse model, that newly formed arteries need overexpression of angiogenic 
factor for approximately 30 days, to be able to mature and retain the gained improvement 
in the blood flow (Dor et al. 2002). In addition, transduction efficacy in humans has not 
reached the levels needed for efficient transgene expression. The differences in the 
immunology and size between humans and experimental models such as rodents and 
rabbits make the interpretation of preclinical results challenging when designing clinical 
studies. 
To be able to provide ischemic tissues sufficient blood flow in terms of gene therapy new 
methods are still needed. On the other hand, there are other diseases or conditions where 
even short term improvement in the perfusion may provide crucial benefit in the morbidity 
or mortality. One example of these conditions is fetal growth restriction which is caused by 
insufficient perfusion of the placenta. In this thesis an overview of current knowledge of 
different aspects of angiogenic gene therapy and regulatory guidelines is provided. In the 
experimental section, studies of new methods for improving angiogenic therapy are 
presented, and a pregnant rabbit model that was established to study the safety and 
feasibility of the intra uterine gene transfer for the treatment of intra uterine growth 
restriction is reported. 
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2 Review of the literature 
2.1 DISEASES AND DISORDERS FEASIBLE FOR ANGIOGENIC GENE 
THERAPY 
Ischemia is a condition where tissues do not get sufficient amounts of nutrients and oxygen 
due to diminished blood flow leading to atrophy, malfunction or even necrosis of the 
tissue. Delivery of angiogenic growth factors to these tissues by means of angiogenic gene 
therapy has been studied both in pre-clinical and clinical trials (Table 1). There are several 
ischemic diseases and disorders that would benefit from increased blood flow, such as 
coronary artery and peripheral artery diseases (CAD and PAD, respectively) that are 
caused by atherosclerosis (Ylä-Herttuala et al. 2007).  
 
Table 1. Completed angiogenic gene therapy clinical trials. Modified from Vuorio, Jauhiainen, 
and Ylä-Herttuala (2012) and Zachary and Morgan (2011).  
Vector Gene Disease Result 
(primary end point) 
Reference 
Recombinant protein FGF-2 CAD 
PAD 
Negative 
Positive 
(Simons et al. 2002) 
(Lederman et al. 2002) 
 GM-CSF CAD Positive (Seiler et al. 2001) 
 VEGF-A165 CAD Negative (Henry et al. 2003) 
Plasmid DNA Del-1 PAD Negative (Grossman et al. 2007) 
 FGF-1 PAD Negative (Nikol et al. 2008) 
 HGF PAD Negative (Powell et al. 2008) 
 VEGF-A165 CAD 
PAD 
Negative 
Negative 
(Stewart et al. 2009) 
(Kusumanto et al. 2006)  
 VEGF-A165 –FGF-2 CAD Negative (Kukuła et al. 2011) 
Adenovirus FGF-4 CAD Negative (Henry et al. 2007) 
 HIF-1α –VP16 PAD Negative (Creager et al. 2011) 
 VEGF-A121 CAD 
PAD 
Positive 
Negative 
(Stewart et al. 2006) 
(Rajagopalan et al. 2003) 
 VEGF-A165 CAD 
PAD 
Positive 
Positive 
(Hedman et al. 2003) 
(Mäkinen et al. 2002) 
Ang, angiopoietin; CAD, coronary artery disease; Del-1, developmentally regulated endothelial cell locus 
1; FGF, fibroblast growth factor; GM-CSF, granulocyte/macrophage colony stimulating factor; HGF, 
hepatocyte growth factor; HIF, hypoxia inducible factor; PAD, peripheral artery disease; VEGF, vascular 
endothelial growth factor. 
 
2.1.1 Peripheral and coronary arterial disease 
 
Atherosclerosis related arterial narrowing, i.e. plaque formation, is present in, but not 
limited to the peripheral vascularity, as well as in the coronary arteries where the most 
know symptoms, heart failure and angina, occur. In the periphery the condition is called 
peripheral arterial disease and affects primarily arteries in the lower limbs, most often the 
iliac and femoral arteries. Reduced blood flow to peripheral leg causes pain during exercise, 
a condition known as a claudication. The growing plaques further reduce blood flow and 
may block it totally. As a result the pain becomes constant and later ulcers or even 
gangrene may develop (Garasic and Creager 2001; Ouriel 2001; Waters et al. 2004). 
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Lower limb ischemia can be classified as acute or chronic. Acute ischemia is most often 
caused by embolus originated from the heart during atrial fibrillation, whereas chronic 
ischemia is caused by atherosclerotic arterial narrowing. Critical ischemia can also develop 
in limbs of PAD patients if the atherosclerotic plaque ruptures and concomitant thrombus 
formation blocks blood flow in the artery. Acute ischemia requires immediate surgical 
intervention whereas chronic ischemia caused by PAD has more treatment options 
(Kuukasjärvi, Salenius, and Riekkinen 1997; Lepäntalo 1995). 
To diagnose chronic PAD, blood pressure from ankle and brachium are measured and 
an index is calculated. If the ankle-brachial index (ABI) is less than 0.95 PAD is diagnosed. 
However, pain is usually not yet present at this point and according to the Fontaine 
classification this state is classified as class I (Lepäntalo 1995). When ABI is 0.5 – 0.9 pain is 
felt during exercise i.e. claudication occurs (class II), and if ABI decreases below 0.5 rest 
pain is present (class III), and tissue damage start to develop which is a sign of critical 
ischemia (class IV). Angiography is used to verify the diagnosis of PAD and it also reveals 
the place of occlusion (van den Bosch et al. 2002; Ouriel 2002; Ouriel 2001). 
The most important treatment of PAD is lipid-lowering therapy with statins, the optimal 
treatment of hypertension and diabetes, cessation of smoking and the use of antiplatelet 
drugs. Current invasive treatments for critical ischemia include by-pass surgery, 
endarterectomy, angioplasty and stenting (Setacci et al. 2011). If the treatment is started in 
the early stage when claudication is the only symptom, results are relatively promising. 
However, the further the disease has developed the worse the prognosis is, for example, up 
to 40 % of superficial femoral arteries treated with angioplasty and stenting suffer from 
restenosis three years after the operation (Muradin et al. 2001). Self-expanding and coated 
stents have shown some improvement (Setacci et al. 2011). A study using drug eluting 
stents to treat below the knee arteries, showed promising preliminary results with up to 80 
% patency rates five years after the operation (Werner et al. 2012). However, there still 
remains a group of patients who do not benefit from current treatments and may be 
candidates for gene therapy. 
Similarly to the PAD, arterial narrowing due to the atherosclerosis is common in the 
coronary arteries causing coronary arterial disease (CAD). This disease has two different 
clinical manifestations: Stable angina and acute coronary syndromes. Stable angina is a 
stage where the growing plaque has a thick fibrous cap and is lipid-poor. The plaque 
diminishes blood flow to myocardium and induces ischemia to the distal part of the tissue, 
causing pain during exercise. However, if the plaque is unstable and ruptures, then 
thrombosis occurs. If the occlusion of the artery by thrombosis is transient or do not 
completely block the blood flow, the condition is termed non-ST-segment elevation 
myocardial infarction (NSTEMI) causing endomyocardial infarction. But if the thrombosis 
occludes the artery completely the patient suffers from transmural MI (ST-segment 
elevation myocardial infarction i.e. STEMI). Treatment options for severe CAD and MI are 
essentially the same as for PAD. Stable angina and acute coronary syndrome can be treated 
with medical therapy. However, medical therapy may be inadequate to alleviate the 
symptoms, or the severity of CAD worsens the prognosis of the patient. Thus, if no 
contraindications exists, percutaneous coronary intervention (PCI) or coronary bypass 
surgery can be performed (Ashley and Niebauer 2004). 
 
2.1.2 Fetal growth restriction 
 
There is a significant number of pregnancies that are affected by fetal growth restriction 
(FGR). It has been evaluated that in up to 10 % of all pregnancies fetuses are not able to gain 
their genetically determined growth potential (Bamfo and Odibo 2011). There are various 
reasons that can hinder fetal growth, i.e. genetic disorders or intra-uterine infections, but 
placental deficiency has been considered to be the main reason for fetal growth restriction 
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(Sankaran and Kyle 2009) and has been estimated to affect up to 3 % of pregnancies 
(Kupferminc et al. 2000). If placental deficiency occurs during the second and third 
trimester the fetus is unable to gain its potential growth. At birth, and also in the late 
pregnancy ultrasound imaging, the signs that reveals FGR are the loss of adipose tissue and 
changes in body proportions (Baschat 2004). Restriction of growth can often cause stillbirth, 
alternatively, the neonates that survive usually suffer from many disorders, i.e. respiratory 
defects and retinopathy (Garite, Clark, and Thorp 2004). In fetal development, the third 
trimester is crucial for gain of essential body fat storages to maintain myelination and 
retinal function prior to and after birth (Baschat 2004). Figueroa and Maulik (2006) have 
reviewed a large variety of studies with different approaches to treat FGR prenatally such 
as maternal oxygen administration, nutrient supplement and pharmaceutical 
administration. The efficacy of treatment was either absent or the results were controversial 
in terms of improvement of fetal growth compared to the controls. Some evidence of 
improvement of placental perfusion was found when vasodilative drugs were used but 
those studies had either other concerns or small patient numbers. A case report of one fetus 
treated with amino acids and glucose supplementation through canullated umbilical vein 
for 18 days showed significant fetal growth gain but treatment was terminated due to 
anticipated infection (Tchirikov et al. 2010). 
During placentation maternal spiral arteries are dilated to provide blood supply to the 
placenta. To adequately develop this vascularization trophoblasts invade in the 
myometrium (Bamfo and Odibo 2011). In this process smooth muscle cells and elastic 
lamina are removed from the spiral arteries in the inner third of the myometrium. In 
addition, there is five to ten fold dilation of the vessel in the vicinity of the placenta. If this 
dilation of the spiral arteries is inadequate, high blood velocity in the intervillous space 
develops which may cause disruption of villi and diminishes the time for oxygen and 
nutrient exchange (Burton et al. 2009). This lack of dilatation of the spiral arteries causes 
also many unperfused areas in placentas as Brunelli and coworkers (2010) showed in their 
study of intrauterine growth restriction in the beginning of third trimester. However, there 
were no infarctions observed which suggests vasculature was inadequately dilated 
(Brunelli et al. 2010). This allows room for speculation whether stimulation of the 
trophoblasts could result in further invasion and dilation of the spiral arteries, thus 
providing sufficient blood supply to the placenta and fetus. 
2.2 ANGIOGENIC GENE THERAPY 
2.2.1 Angiogenesis 
 
During early embryonic development a vascular network is formed by the angioblasts in 
the process called vasculogenesis. It has been shown that progenitor cells involved in 
vasculogenesis arise from both intra- and extra-embryonic tissue. Indeed, the cells originate 
from the embryonic mesoderm, as well as the extra-embryonic yolk sac, allantois and 
placenta (Patel-Hett and D’Amore 2011). All the capillary vessel growth, dilatation and 
sprouting thereafter is termed angiogenesis. Collateral arterial growth in response to the 
occlusion of the main artery e.g. in the lower limbs or myocardium is called arteriogenesis. 
Angiogenesis can be described as a sequence of different events; vessel dilatation increases 
vascular permeability, extracellular matrix degrades, activated endothelial cells migrate 
and eventually form lumens (Conway, Collen, and Carmeliet 2001). 
Angiogenesis involves a large variety of different regulators and factors, i.e. oxygen 
level, shear stress caused by blood flow and different cytokines and their inhibitors. 
Hypoxia has been shown to increase vascular endothelial growth factor (VEGF) mRNA 
levels in myocardium and other tissues (Banai et al. 1994). Endothelin (Kourembanas et al. 
1991) and platelet derived growth factor B (PDGF-B) (Kourembanas, Hannan, and Faller 
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1990) mRNA expression in cultured umbilical vein endothelial cells and basic fibroblast 
growth factor (bFGF) circulating protein are also increased in limb ischemia patients 
(Rohovsky et al. 1996), all of these are associated with angiogenesis. On the other hand, 
blood flow induced shear stress has opposite functions to hypoxia. It was found that the 
mRNA level of endothelin precursor was decreased in human umbilical cord endothelial 
cells when they were subjected to the flow (Sharefkin et al. 1991). Cytokines and inhibitors 
involved in angiogenesis are listed in the table 2. In adults, angiogenesis is mainly present 
in wound healing, in bone formation, follicle and hair growth and in corpus luteum and 
endometrium development during menstrual cycle. In addition, pathological angiogenesis 
occurs especially in malign tumors and diabetic retina (Carmeliet 2003). 
 
Table 2. List of factors that stimulate and inhibit angiogenesis as stated by Conway, Collen, and 
Carmeliet (2001). 
Factor Stimulator/Inhibitor Receptor Function 
VEGFs 
(A, B, C, 
D,[E, F], 
PlGF) 
Stimulator VEGF-Rs 
(1, 2, 3) 
Increases vascular permeability by stimulating 
eNOS, stimulates endothelial cell proliferation and 
migration. 
Ang-1 Inhibitor Tie-2 Decreases vascular permeability. 
Ang-2 Stimulator  Enhances endothelial sprouting (antagonist to Ang-
1). 
MMPs Stimulator e.g. CD44 Extra cellular matrix and basement membrane 
degradation liberates VEGF and bFGF. 
TIMPs Inhibitor  Inhibits MMPs. 
TSP-1 Inhibitor  Inhibits MMP-2 and -9 activation. 
FGFs Stimulator FGF-Rs Stimulates endothelial cell growth, recruits 
mesenchymal and inflammatory cells. 
PDGF-BB Stimulator PDGF-Rs Recruits pericytes and smooth muscle cells. 
Ang, angiopoietin; eNOS, endothelial nitric oxide synthase; FGF, fibroblast growth factor; MMP, matrix 
metalloproteinase; PDGF, platelet derived growth factor; PlGF, placental growth factor; Tie, tyrosine kinase 
with immunoglobulin-like and EGF-like domains; TIMP, tissue inhibitor of metalloproteinase; TSP, 
Thrombospondin; VEGF, vascular endothelial growth factor. 
 
2.2.2 Vascular endothelial growth factors 
 
The human VEGF family consists of five members: VEGF-A, B, C, D and placenta growth 
factor (PlGF). In addition, there are two non-human proteins included to the family, VEGF-
E and F. VEGF-A is a secreted protein which binds to heparin. It was isolated and the 
coding gene sequenced by Gospodarowicz, Abraham, and Schilling (1989). The gene was 
also found to encode several isoforms of the protein (Leung et al. 1989). The VEGF-A gene 
consists of eight exons separated by seven introns and either by alternative mRNA splicing 
or proteolytic cleavage different sized proteins are formed. To date 121, 145, 165, 183, 189 
and 206 amino acid (aa) long isoforms have been identified, of which the 165 aa isoform has 
been recognized as the most potent angiogenic factor. Different isoforms have partially 
overlapping but also different functions (Jussila and Alitalo 2002; Tischer et al. 1991). There 
is also a splice variant of VEGF-A165 with an alternative terminal 6 amino acid sequence 
followed by a stop codon, called VEGF165b, that has been shown to have anti-angiogenetic 
properties in normal tissue and was downregulated in tumors (Bates et al. 2002). 
VEGF-A is a ligand for VEGF receptors 1 and 2 (Figure 1). In addition, the isoforms bind 
to neuropilin receptor and extracellular matrix heparan sulphate, except for the shortest 
isoform 121 aa which lacks the heparan binding domain (Ferrara 2004). In addition to 
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vasculogenesis and angiogenesis, VEGF-A plays a key role in female reproductive organ 
development during menstrual cycle (Cullinan-Bove and Koos 1993) and in bone formation 
(Gerber et al. 1999). It is also present in pathological conditions such as cancer and retinal 
diseases (Ferrara 2000). 
Two isoforms of VEGF-A, 121 aa and 165 aa, have been used in clinical trials to treat both 
CAD and PAD using either plasmid or viral vectors. Both delivery methods and isoforms 
were shown to be safe and some improvements in the disease were detected. However, 
efficacy of these treatments has been based on the clinical end points, yet there is no 
validated means to measure increase in perfusion, the most relevant outcome of angiogenic 
gene therapy (Gupta, Tongers, and Losordo 2009). 
 
Figure 1. Vascular endothelial growth factor (VEGF) receptors and their ligands. Ligands in 
parenthesis are non-mammalian homologues. PLGF, placental growth factor; VEGFR, VEGF 
receptor; NRP, neuropilin;  
* = extracellular space; ** = cell membrane; *** = cytoplasm.  
Modified from Patel-Hett and D’Amore (2011). 
 
The second member of the VEGF family, VEGF-B, was found to be produced as two 
different isoforms, 167 aa and 186 aa. The smaller isoform binds to the VEGFR-1, neuropilin 
receptor (NRP)-1 and heparan. The longer isoform is secreted and soluble. However, if this 
isoform is proteolytically cleaved the NRP-1 binding epitope is revealed (Olofsson et al. 
1996a; Olofsson et al. 1996b). The biological function of VEGF-B is not fully understood. It 
has been proposed to act by forming heterodimers with VEGF-A and binding to VEGFR-2 
(Jussila and Alitalo 2002). Recent studies have indicated its specific role in cardiac 
angiogenesis, as shown in pig myocardium by overexpression with adenovirus 
(Lähteenvuo et al. 2009). These effects were thought to be mediated through VEGFR-1 and 
NRP-1. 
VEGF-C and VEGF-D form a subgroup within the VEGF family. They both are ligands to 
VEGFR-2 and -3. They are secreted as a long form but can be proteolytically cleaved both at 
the N- and C-terminal (Achen et al. 1998; Joukov et al. 1996). The longer isoforms are 
ligands to VEGFR-3 and mediate lymphatic growth whereas proteolytically cleaved mature 
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isoforms bind also to the VEGFR-2 and are involved in angiogenesis (Jussila and Alitalo 
2002). This was shown in animal models when different VEGF-D isoforms were 
overexpressed in rabbit skeletal muscle. Mature isoform, named VEGF-DΔNΔC, induced 
capillary growth comparable to the VEGF-A gene transfer whereas the long isoform 
induced lymphatic vessel growth and dilatation (Rissanen et al. 2003). In healthy adults, 
VEGF-D is expressed in the skeletal muscle, heart, lungs, small and large intestine and in 
vessel wall (Achen et al. 1998; Rutanen et al. 2003). In cancer, there are changes in VEGF-C 
and VEGF-D expression levels. In lung cancer, high levels of VEGF-C in addition to low 
levels of VEGF-D predicted metastatic state, however, when both levels were high 
metastasis was not detected (Niki et al. 2000). While VEGF-C is essential for lymphatic 
development (Kärkkainen et al. 2004) the specific role of VEGF-D is still unknown since the 
VEGF-D deficient mice develop normally and are fertile (Baldwin et al. 2005). 
PlGF is also a member of the VEGF family and a VEGFR-1 ligand. It has been proposed 
that PIGF competes with VEGF-A in binding to VEGFR-1 which subsequently increases the 
amount of free VEGF-A available for VEGFR-2 binding and hence promotes angiogenesis. 
PlGF also forms dimers with VEGF-A (Maglione et al. 1991; DiSalvo et al. 1995). In addition 
to placenta, PlGF is expressed in the thyroid in the physiological condition (Viglietto et al. 
1995). However, in other tissues PlGF is only expressed in pathological conditions as 
reviewed by Cao (2009). In addition, cancer therapy targeted to VEGF-A seems to induce 
PlGF expression and promote tumor angiogenesis, thereby counteracting the reduced 
VEGF-A mediated angiogenesis (Cao 2009). 
In addition to members of human VEGF family there are proteins from other sources 
that share similar functions if they become present in mammals. Orf virus genome contains 
a sequence similar to the VEGF-A and the protein produced is as effective as VEGF-A165 in 
inducing endothelial cell proliferation and vascular permeability. It binds to the VEGFR-2 
and NRP but not to heparan sulphate and has been named as VEGF-E (Ema et al. 1997). 
Another VEGF-A165 equivalent has been found in snake venom. This protein binds only to 
the VEGFR-2 with similar affinity as VEGF-A165. The scientists who discovered this protein 
proposed that it be named VEGF-F (Yamazaki et al. 2003). 
 
2.2.2.1 VEGFR-1 and its mechanisms of action 
 
There are three members in the VEGF family that are able to bind to the VEGFR-1: VEGF-A, 
VEGF-B and PlGF. In addition to the endothelial cells, VEGFR-1 is expressed in the bone 
marrow progenitor cells, monocytes, macrophages, vascular smooth muscle cells, 
trophoblasts, renal mesangial cells and various tumor cells (Neufeld et al. 1999; Cao 2009). 
VEGFR-1 is able to activate different cell fate cascades (Figure 2). It is thought that in the 
blood vessels the main function of VEGFR-1, especially its soluble form, is to act as a decoy 
receptor for VEGF-A, to reduce the amount of free protein that could activate the VEGFR-2 
signaling pathway (Shibuya 2006). However, there are some specific actions mediated 
through VEGFR-1 as well, including inflammatory responses. Even though VEGFR-1 
stimulation in adult shows only week angiogenic effects, the deletion of VEGFR-1 gene 
leads to embryonic lethality due to disorganization of the vasculature network. In addition, 
VEGFR-1 phosphorylation may induce VEGFR-2 transphosphorylation (Cao 2009). 
While VEGFR-1 tyrosine kinase activity is rather weak in endothelial cells, in other cell 
types (e.g. monocytes) VEGFR-1 activation modulates the phosphatidylinositol 3-kinase–
Akt pathway, the ERK mitogen-activated protein kinase pathway, and the Janus kinase–
signal transducer and activator of transcription 3 pathway. Moreover, different ligands 
have distinct phosphorylation properties; for example, tyrosine kinase Y1309 is 
phosphorylated by PlGF but not by VEGF-A (Autiero et al. 2003). However, the biological 
function and importance of these activated pathways in different cell types is still under 
investigation (Koch and Claesson-Welsh 2012). 
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Figure 2. Cellular responses to the VEGFR-1 activation. 
 
2.2.2.2 VEGFR-2 and its mechanisms of action 
 
Both VEGF-A and VEGF-DΔNΔC induced angiogenesis is mediated through VEGFR-2 
tyrosine kinase signaling pathway. In addition, proteolytically processed VEGF-C binds to 
the VEGFR-2. Interestingly, the binding affinity of VEGF-A to VEGFR-2 is significantly 
lower than to VEGFR-1 (Waltenberger et al. 1994). Similarly to VEGFR-1, VEGFR-2 has both 
cell membrane anchored and soluble forms. The trans-membrane form is mainly expressed 
in the endothelial cells and is responsible for endothelial cell differentiation, proliferation, 
migration, and formation of vascular tubes. The soluble form is present in skin, heart, 
spleen, kidney, ovary, and plasma (Koch and Claesson-Welsh 2012), and has also been 
shown to bind VEGF-C, thus it also has a role in the regulation of lymphangiogenesis 
(Albuquerque et al. 2009). Until recently the tyrosine kinase phosphorylation and 
subsequent signaling were thought to occur at the cell membrane bound receptor 
immediately after the ligand binding and that the subsequent endocytosis led to the 
degradation of the receptor-ligand complex, thus terminating the signaling. However, 
recent studies have shown that a diversity of signaling can also occur after the receptor-
ligand complex has been internalized by endocytosis (Eichmann and Simons 2012). 
Endothelial proliferation after VEGF-A-induced VEGFR-2 activation occurs through 
RAS/RAF/ERK/MAPK signaling pathways mediated by Y1175 phosphorylation of the 
PLCγ and subsequent activation of the PKC. Phosphorylation of other tyrosines, e.g. Y951, 
Y1175 and Y1214, leads to the binding of other signaling molecules, such as TSAd, SHB and 
NCK, respectively, inducing the endothelial cell migration, survival and permeability 
(Figure 3; Koch and Claesson-Welsh 2012). 
10 
 
 
 
Figure 3. Endothelial cell responses to the VEGFR-2 activation. Modified from Koch and 
Claesson-Welsh (2012). 
 
2.2.3 Notch signaling in angiogenesis 
 
Cell to cell interaction dependent Notch signaling is a highly conserved cell fate and 
differentiation mechanism within Metazoa. There are four different Notch receptors (Notch 
1-4) and five ligands (Jagged [Jag] 1 and 2; Delta-like [Dll] 1,3 and 4) in mammals. Both 
receptors and ligands are type 1 trans-membrane proteins. The Notch receptors have an 
extracellular domain containing several Ca+ binding repeats, which are necessary for the 
receptor-ligand binding, a trans-membrane and an intracellular regions containing domains 
for transcriptional coactivators and nuclear-localization signals, a transactivation domain 
and a C-terminal PEST sequence. The ligands consist of an N-terminal DSL domain, 
variable numbers of EGF-like repeats, a trans-membrane region, and a variable intracellular 
tail. Notch signaling is crucial in embryonic development due to its fundamental role in the 
decisions of cell fate (Aster, Pear, and Blacklow 2008; Espinoza and Miele 2013; Quillard 
and Charreau 2013). 
Notch signaling also plays a major role in the regulation of the angiogenic sprouting in 
adults. The tip cell, a distinct type of endothelial cell, is specialized to lead the sprouting 
vessel towards the higher concentration of VEGFs. It expresses high levels of VEGFR-2 and 
Dll4, of which the latter is the key mediator in the regulation of the cell type for the 
neighboring endothelial cells (Thomas et al. 2013). Tip cell Dll4 is a ligand for Notch1 
receptor of the neighboring endothelial cell and this binding has been shown to be the key 
event determining the cell fate of the proceeding endothelial cell, that is phenotype of a 
stalk cell and not a tip cell (Figure 4; Hellström et al. 2007). 
In the Notch signaling cascade the first step after receptor-ligand binding is the cleavage 
of the extracellular domain of the Notch by metalloproteases, followed by immediate 
intramembrane cleavage of the receptor by γ-secretase, a multiprotein protease complex. 
The latter cleavage releases the active intracellular form of the Notch (ICN). ICN is then 
translocated to the nucleus where it forms a nuclear transcription complex with a core 
binding factor (CBF)-1, Suppressor of Hairless (Su(H)) and Lag-1 (CSL, also known as RBP-
Jκ) and with cofactors of the Mastermind-like (MAML) family. This complex activates the 
transcription of the genes specified by the CSL binding sites (Aster, Pear, and Blacklow 
2008). It was show that the use of compounds inhibiting the cleavage of amyloid precursor 
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protein also interferes with the proper function of γ-secretase (Searfoss et al. 2003). These 
compounds were named γ-secretase inhibitors (GSIs) and have been used, among other 
purposes, to inhibit Notch signaling. In the developing vasculature, inhibiting the function 
of γ-secretase with these compounds led to the overexpression of the tip cells and vascular 
sprouting due to the diminished Notch1 receptor – Dll4 signaling (Hellström et al. 2007). 
It was noted in an early in vitro study with T-lineage acute lymphoblastic leukemia (T-
ALL) cell line that GSI effectively inhibited Notch1 signaling and down regulated Notch1 
target genes. In addition, it was noted that the GSI treatment induced G1 cell cycle arrest. 
However, when a clinical trial was conducted to treat T-ALL patients with oral GSI an 
unfavorable gastrointestinal toxicity was noted. It was thought to be a consequence of the 
inhibition of the Notch signaling in the intestinal epithelium where both Notch1 and 
Notch2 signaling play significant roles in the cell differentiation and proliferation. As it has 
become clear that GSIs inhibit signaling of all Notches their development as drug 
candidates has been attenuated (Redmond et al. 2011). 
 
Figure 4. Notch signaling dependent endothelial cell fate determination. 1) VEGFR-2 activation 
of the tip cell by VEGF-A induces Dll4 expression. 2) Notch1 of the neighboring endothelial cell 
binds to Dll4, intracellular form of Notch1 (NITC) is cleaved by γ-secretase and transported to 
the nucleus. 3) NITC forms a nuclear transcription complex with CLS (among others) and 
activates the genes that are responsible for the cell to take stalk cell phenotype. 
 
2.2.4 Gene therapy vectors 
 
Transferring genetic material in cells to treat both inherited and acquired diseases 
(examples of the latter being cardiovascular diseases and cancer) with vectors has been 
under intensive research for over two decades. There have been numerous successful pre-
clinical studies and several clinical studies as well (summarized in Table 3) but outside of 
China only one gene therapy product has achieved the marketing authorization (Kastelein, 
Ross, and Hayden 2013). 
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Table 3. Number of clinical trials with different vectors (modified from the Journal of Gene 
Medicine on July 3rd 2013 [http://www.wiley.com/legacy/wileychi/genmed/clinical/], updated 
in January 2013). 
Viral vectors No % 
Non-viral vectors/ 
no vector 
No % 
Combination/ 
unknown 
No % 
Adenovirus 437 23.0 Naked/Plasmid DNA 346 18.2 
Naked/Plasmid DNA 
+ Adenovirus 
3 0.2 
Retrovirus 375 19.7 Lipofection 112 5.9 
Naked/Plasmid DNA 
+ Vaccinia virus 
2 0.1 
Vaccinia virus 119 6.3 RNA transfer 31 1.6 Unknown 64 3.4 
Adeno assosiated 
virus 
99 5.2 Others 46 2.4 
   
Poxvirus 67 3.5 
      
Lentivirus 62 3.3 
      
Herpes simplex virus 60 3.2 
      
Poxvirus + Vaccinia 
virus 
28 1.5 
      
Others 51 2.7 
      
Total of 1902 clinical trials performed/ongoing by the end of year 2012. Others include vectors with less 
than 10 trials. 
 
2.2.4.1 Adenoviruses 
 
Adenoviruses were the first group of human pathogen viruses isolated and characterized. 
This group of pathogens is divided in mast-adenoviruses, i.e. mammalian pathogens, and 
avi-adenoviruses, i.e. avian (bird) pathogens. These two classes have several sub-classes. 
Adenoviruses are non-enveloped double stranded DNA viruses, that are 70-100 nm in 
diameter. They are non-integrating viruses and their genome is transcribed in the host cell 
nucleus. As a human pathogen adenoviruses commonly cause respiratory infections (Shenk 
1996; Kootstra and Verma 2003). Adenovirus binds to the cell membrane coxsackievirus 
and adenovirus receptor (CAR) with the knob of the fiber on the viral surface (Bergelson et 
al. 1997). CAR is expressed in a wide variety of human cells, with the highest expression 
seen in pancreas, brain, heart, small intestine, testis, and prostate and less in liver and lungs 
(Tomko, Xu, and Philipson 1997). 
Due to their well know characteristics, adenoviruses have been employed as tools to 
transfer genetic material into mammalian cells. To make space for transgene and to 
improve safety, one or more of the immediate early elements (E1A, E1B, E2, E3 and E4) can 
be deleted. There can be up to 9 kilobase (kb) of foreign material incorporated into the 
adenovirus. The most commonly used serotype in gene therapy is 5 with deletions of E1 
and E3 allowing transgene insertion approximately 7.5 kb in size (Kootstra and Verma 
2003). These adenoviruses are produced in cell lines which expresses the necessary E1 
element that is deleted from the vector backbone (Lusky 2005). Adenoviruses have been 
used widely over a decade both in animal models and in humans to treat a variety of 
diseases from ischemia to cancer as a replication deficient vector carrying transgene or as a 
replication competent oncolytic virus targeted to the cancerous cells (Fueyo et al. 2000; 
Sandmair et al. 2000; Mäkinen et al. 2002; Tyynelä et al. 2002; Brevetti et al. 2003; Hedman et 
al. 2003; Kopp et al. 2004; Rutanen et al. 2004). The limitation of the use of adenoviruses is 
the immune response that halts the transgene expression approximately two weeks after 
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gene transfer by inactivating cells that are transduced by the virus. In addition, humoral 
immunity may prevent efficient re-administration of adenoviruses (Kafri et al. 1998). 
 
2.2.4.2 Baculoviruses 
 
Baculoviruses are divided in two main classes, nucleopolyhedroviruses (NPV) and 
granuloviruses (GV). There are no known diseases caused by baculoviruses in other 
animals outside of the phylum arthropoda (Miller 1997). There are several hundreds of 
baculovirus species and they mainly infect a variety of caterpillars. Other known hosts 
include hymenoptera, fly, silverfish, caddis fly and clam. The most thoroughly studied 
baculovirus is Autographa californica multiple NPV (AcMNPV). Its genome, double stranded 
DNA over 133 kb in size, has been fully sequenced (Ayres et al. 1994; Federici 1997). 
In nature, AcMNPV exists in two different forms, the budded virus (BV) and the 
occlusion derived virus (ODV). Occlusion particle is surrounded with tight polyhedron 
which is covered with protein capsid and the virus is surrounded by an envelope 
originated from host cell nucleus. BV has a protein capsid which contains the genome and 
its envelope is from the host cell membrane and thus contains mainly lipids (Funk, 
Braunagel, and Rohrmann 1997). 
ODV can stay infectious in the environment for years. It is between 0.5 and 15 µm in 
diameter, includes several virions and gets into host while it feeds. Caterpillars have a 
highly basic gut which causes polyhedron to dissemble and virions are released. Virion 
envelope is then fused with gut endothelial cell microvillus and the genome containing 
capsids are released into the cytoplasm. Capsid is then transferred to the nucleus where 
genome replication occurs and new genomes are packed in the capsids. Capsids are 
transferred to the cell membrane where they bud out with the gp64 incorporated cell 
membrane derived envelope and form BV. BV then spreads the infection within the host 
organism via hemolymph (Figure 5). Infected cells produce both BVs and ODVs until the 
death of the host and ODVs are released to the environment and are eventually eaten by a 
new caterpillar (Airenne et al. 2004; Federici 1997). 
BVs have been developed to serve as a vector to transfer genetic material. At first 
baculoviruses were used as pesticide. After a protein toxic to insects was incorporated in 
the baculovirus genome the efficacy was similar to the chemical pesticides (Black et al. 
1997). Since the genetic manipulations were feasible possibilities of baculovirus usage has 
increased significantly. If a foreign gene is incorporated under a viral promoter in the virus 
genome, target cells, with their cellular machinery, produce desired protein. Especially 
protein research has benefited from the hundreds of mammalian proteins produced by 
insect cells (Kost, Condreay, and Jarvis 2005). 
After introducing the AcMNPV derived bacmid vector, the insertion of transgenes and 
production of recombinant baculoviruses has become easy and fast. Recombinant 
baculoviruses can be produced within 10 to 12 days (Luckow et al. 1993). This generated 
interest among the field of gene therapy, especially after the successful transduction of 
mammalian cells with recombinant baculoviruses (Hofmann et al. 1995). To date 
baculoviruses have been used in many pre-clinical studies both in immune deficient and 
immune competent animal models but the efficacy has not yet achieved the level that in 
vitro results have implied. The complement system has been thought to be the main 
obstacle especially if the model has a functional immune system. In addition to attempts to 
circumvent the complement system, modifications to baculovirus envelop and expression 
cassette have been employed to enhance the transduction efficacy (Airenne et al. 2010). 
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Figure 5. Baculovirus lifecycle in nature. 1. The protein matrix of the ODV is dissembled in the 
alkaline midgut of the caterpillar and virions fuse to the gut epithelium cell membrane. 2. 
Nucleocapsids are transported to the nucleus where the viral transcription and replication 
occurs. In addition, portion of the capsids are transported directly to the basolateral side of the 
cell. Nucleocapsids bud out from the cell to the hemolymph with a cell membrane derived 
envelope where gp64 is incorporated. 3. Budded viruses spread within the hemolymph and 
infect further cells where both BVs and ODVs are formed. 4. Infected cells produce ODVs until 
finally lysed, occlusion bodies are released to the environment and eventually eaten by another 
caterpillar. 
 
2.2.4.3 Other viral and non-viral vectors 
 
In addition to adenoviruses and baculoviruses, a large variety of other vectors, both viral 
and non-viral have been studied as vehicles to transduce genetic material into cells. In 
addition to the origin, vectors can be divided as integrating and non-integrating vectors. 
While adenoviruses and baculoviruses lack the ability to integrate in the host genome, 
retroviruses and adeno-associated (AAV) viruses are commonly used vectors that integrate 
the transgene in the host cell genome. Retroviruses are a broad group of viruses including 
oncoretroviruses, lentiviruses and spumaviruses. They are enveloped viruses, 
approximately 100 nm in diameter, with 7 – 10 kb linear single stranded RNA genome. 
Retroviruses can carry up to 8 kb transgene. After retroviral infection viral RNA is reverse 
transcribed to DNA and then integrated into the host cell genome (Goff 1992). 
Oncoretroviruses, such as murine leukemia virus, were the first retroviruses used as gene 
transfer vectors in both pre-clinical models and clinic. However, they lack the capability to 
transduce non-dividing cells. Lentiviruses, on the other hand, transduce both dividing and 
non-dividing cells. In addition, the integration sites of oncoretroviruses are thought to be 
more harmful compared to the ones with lentiviruses (Kootstra and Verma 2003; Bushman 
2007). 
Retroviruses have been used as a method to correct a deficient gene in patients suffering 
from e.g. X-linked severe combined immunodeficiency (X-SCID). Altogether 20 children 
have been treated in three different studies in France, England and Australia by the end of 
year 2011. However, five of the patients developed T-cell leukemia, due to the insertional 
mutagenesis by the vector. Four of the patients with leukemia were successfully treated 
but, unfortunately, one passed away. This drawback, even though all the survivors were 
able to develop rather normal immune cell population, temporarily halted the clinical 
15 
 
 
research. In addition to X-SCID, according to review by Ginn and Alexander (2012) two 
other congenital immune deficiency diseases (adenosine deaminase deficiency and X-linked 
adrenoleukodystrophy) treated with retroviruses have shown promising results by 
correcting the phenotype of the immune cells. Moreover, the research to improve the 
retroviral safety, especially the development of lentiviral vectors, have given this gene 
therapy approach renewed potential for use in new multinational trials (Hacein-Bey-Abina 
et al. 2010; Ginn and Alexander 2012). There are also attempts to direct the transgene 
integration to the safer locations, such as ribosomal DNA, to minimize the risk of activating 
oncogenes (Schenkwein et al. 2013). 
AAV is a small, 25 nm in diameter, non-enveloped virus with 5 kb linear single strand 
DNA genome. AAV is capable of integrating into the host cell genome but virus replication 
does not start until the cell is co-infected with another virus, e.g. adenovirus. In addition, it 
has been shown that only 10 % of AAVs that infect cells do integrate into the host cell 
genome. There are no known diseases attached to AAV (Hüser, Weger, and Heilbronn 
2002). If the AAV genome, apart from the inverted terminal repeats (ITR), is replaced with a 
transgene, the integration capability is reduced but the transgene expression does not 
require subsequent infection with another virus. In addition, the therapeutic protein is 
produced from both integrated and episomal DNA for a relative long period of time. 
Furthermore, a wide variety of tropism can be achieved by using different AAV serotypes 
(Kootstra and Verma 2003; Deyle and Russell 2009). AAVs are currently used in an 
increasing number of clinical trials targeting inherited diseases, including the first 
approved gene therapy product in Western World for the treatment of the lipoprotein 
lipase (LPL) deficiency (Kastelein, Ross, and Hayden 2013; Mingozzi and High 2011). In 
addition, a clinical trial has been conducted using AAV based vectors to treat patients with 
mutations in the gene encoding retinal pigment epithelium-specific 65-kDa protein RPE65 
which is associated with poor vision at birth and blindness by early adulthood (Simonelli et 
al. 2010). In this trial, if treatment had been given early enough, remarkable improvement 
in the vision was achieved (Ginn and Alexander 2012). 
Due to the safety concerns associated with the use of viruses, also non-viral vectors and 
other methods have been developed to transfer genetic material to the target cells. Since the 
use of naked DNA, RNA or plasmid DNA alone has shown to be ineffective, a gene gun, 
electroporation and ultrasound have been used to improve gene transfer efficacy. They all 
share the same function, i.e. they induce small pores on the negatively charged cell 
membrane allowing negatively charged nucleic acids to penetrate into the cell. However, 
this method leaves the genetic material unprotected from the nucleases before reaching the 
cell. To overcome this hurdle, nucleic acids have been incorporated into lipids. This 
complex protects genetic material from nucleases and, if produced with higher lipid versus 
nucleic acid concentration, has a positive net charge. This positively charged complex 
interacts with negatively charged plasma membrane which leads to internalization of the 
complex into the cell by endocytosis. The limit of this method is the escape of the complex 
from the endosome.  The endosome can either recycle its content back to the cell membrane 
or fuse with the lysosome to initiate degradation (Zhang et al. 2012). 
 
2.2.5 Regulatory guidelines for safety testing 
 
There are basically three guidelines provided by the European Medicines Agency (EMA) to 
be followed when genetically modified organisms are used in nonclinical studies, especially 
if the aimed patient population includes individuals in fertile age, before applying for the 
permit to conduct a clinical trial. The first one to adopt when designing in vivo studies is the 
“Guideline on the Non-Clinical Studies Required before First Clinical Use of Gene Therapy 
Medicinal Products (GTMP)” (EMA 2008). If patients in fertile age are to be treated there 
are additional two guidelines that should be followed in preclinical studies, “ICH guideline 
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S5 (R2) – Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male 
Fertility” and “Guideline on non-clinical testing for inadvertent germline transmission of 
gene transfer vectors” (EMA 2006, 2007). None of the guidelines give strict rules or direct 
instructions on how the studies should be performed due to the diverse nature of the gene 
therapy methods. Instead, the guidelines recommend that each study protocol needs to be 
discussed with authorities before the time consuming and expensive good laboratory 
practice (GLP) level in vivo studies are conducted prior to clinical trials. In addition, these 
guidelines are only pertinent to the European Union, and if other regions are included in 
the clinical trials and/or subsequent marketing authorization application, the authorities of 
those regions should be consulted whether the proposed study protocol includes the 
demands of those additional regions. 
 
2.2.5.1 Non-clinical studies before clinical use 
 
The primary function of the first guideline is to provide researchers sufficient background 
information to be able to establish the relevant methods to address the following in the 
preclinical studies: “pharmacodynamic “proof of concept” in non-clinical model(s); bio-
distribution of the GTMP; recommendation on initial dose and dose escalation scheme to be 
used in the proposed clinical trial; identification of potential target organs of toxicity; 
identification of potential target organs of biological activity; identification of indices to be 
monitored in the proposed clinical trial; identification of specific patient eligibility criteria” 
(EMA 2008). 
To be able to demonstrate the proof of concept, study design should include such 
methods (in vivo and/or in vitro) that are able to show the transgene expression in the target 
tissue and its function, either by demonstrating the potential clinical effect in an animal 
model or at least supporting evidence of molecular mechanism of the event in the cell or 
tissue culture if relevant animal models are not available. The next step is to provide 
information of the biodistribution of the vector. This is basically done by giving the 
treatment as it is intended to be administered in the clinical trial and analyzing all tissues 
for the presence of the vector. Depending on the anticipated expression time of the vector 
bio-distribution analysis should be done at several time points after the administration. 
When non-integrating vectors are used, one should be able to provide evidence of 
extinction of the vector from the tissues. Following the biodistribution study, the dose 
escalation study is conducted where it should be possible to show the amount of viral 
particles needed for the effective biological outcome. Together with toxicity studies, which 
also should follow the clinical protocol, an estimation of the doses for clinical studies is 
made that gives maximal biological effect with minimal toxicity to the patient. In addition, 
especially if pediatric patients are treated, integration studies may be required, and if the 
vector has been targeted to certain tissue, it should also be demonstrated that the vector is 
capable of producing biologically significant amounts of the transgene product in the target 
tissue. Immunotoxicity and immunogenicity toward both vector and transgene product, 
particularly with growth factors and cytokines, should also be evaluated even though 
differences between species may cause difficulties in interpreting the data. There should be 
evidence provided whether the devices intended to be used in delivering the vector has any 
contribution in the vector activity. Also, the environmental risk assessment should be 
performed prior the clinical studies. However, genotoxicity studies are not usually required 
and if in silico studies show no oncogenic activity of the vector also carcinogenicity studies 
are not required (EMA 2008). 
In addition to the general guidlines, there are also some specific analyses that should be 
performed depending on the vector used. If plasmid with the antibiotic resistance gene, 
which is generally discouraged, is used as a vector there need to be a study conducted to 
show whether there is an inadvertent expression of such gene in human somatic cells 
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before moving to the clinic. In the case of viral vectors, replication capability should be 
examined, e.g. whether replication-competent viruses are able to form if contact with wild 
type viruses and recombination occurs. If replicating viruses, either fully or conditionally, 
are to be used it should be examined if these vectors behave as expected in both target and 
non-target cells. For instances where integrating vectors have been used to modify cells 
destined for the gene therapy, integration site analysis needs to be performed (EMA 2008). 
 
2.2.5.2 Reproductive toxicity 
 
In addition to the general guideline to be followed for the non-clinical study design, a 
specific guideline is available to design reproductive toxicity study if patients in fertile age 
or pediatric patients are the intended target population. In general, such studies should be 
able to provide information for the following questions: Does the treatment have effect(s) 
on (1) development and maturation of gametes, mating behavior and fertilization of adult 
females and males; (2) pre-implantation development and implantation; (3) embryonic and 
major organ development from implantation to the hard palate closure; (4) fetal and organ 
development and growth; (5) neonatal development and growth until weaning and (6) 
post-weaning development and growth, maturation and gaining full sexual function. In 
addition, adult female reproductive functions are to be evaluated in each step (EMA 2006). 
All reproductive toxicity studies should be performed on mammals, preferably on 
species relatively close to humans. Rats are recommended for use as an animal model for 
most of the reproductive toxicology studies due to the well-defined history of their 
reproductive development. However, due to the administration method, which should be 
the same that is intended to be used in the clinical trials, larger animals may be needed as 
well. Of those, rabbits and non-human primates are the most utilised. In the general toxicity 
studies two different species are commonly needed (rodent and non-rodent). However, In 
most sections of GLP reproductive toxicology studies these are not required, in, especially if 
preliminary studies do not indicate that there are significant differences in metabolism or 
kinetics of the test substance. Additional preliminary tests with lower organisms or tissue 
or cell cultures may be necessary to reduce the number of animals in the final study. For the 
calculation of the number of animals needed the general recommendation is that the 
number of litters per group should be from 16 to 20. Litters exceeding 24 do not greatly 
enhance the precision or consistency (EMA 2006). 
 
2.2.5.3 Germline transmission 
 
When the intended use of efficient gene transfer vectors for therapeutics purposes includes 
humans with potential to procreate, the possibility of the inadvertent vector or transgene 
transmission through germline to the offspring needs to be studied, if the preceding 
biodistribution studies indicate the vector presence in the gonadal tissues. This is due to the 
fact that EU directive 2001/20/EC prohibits any gene therapy trials which result in 
modifications to the subjects germline genetic identity. If the vector is not distributed to the 
gonads or the treated patients are sterile these studies are not necessary. In other cases, a 
flow chart (Figure 6) is to be followed when assessing the possibility to move to the clinical 
trial. In addition, two species (rodent and non-rodent) and both genders need to be studied 
(EMA 2007). 
18 
 
 
 
Figure 6. Flow chart according to the Committee for Medicinal Products for Human Use (CHMP) 
to follow when interpreting results from germline transmission studies. Modified from (EMA 
2007). 
2.3 ANIMAL MODELS FOR PAD, FGR AND REPRODUCTIVE TOXICOLOGY 
2.3.1 Peripheral arterial disease 
 
There are different genetically modified animal models that can be used when peripheral 
arterial disease and different treatment options are studied. Mouse models are the most 
utilised due to the relatively easy genetic manipulation and rapid life cycle. There are 
several mouse models that try to mimic the development of the atherosclerosis in humans. 
The most common are the ones with altered plasma lipid composition induced by knocking 
out genes, altering genes or introducing transgenes that are involved in lipid metabolism, 
such as apolipoproteins B and E and low-density lipoprotein receptor (LDLR). The main 
change in the plasma lipid levels of these animals is the increase of LDL and triglycerides 
(Zhang et al. 1992; Ishibashi et al. 1993; Young 1996). By gross breeding different knockout 
mice with each other and generating double or even triple knockouts, and combining these 
models with high fat diet, a plaque formation similar to humans can be achieved (Heinonen 
et al. 2007). There is also a rabbit model with LDLR mutation available, discovered by 
Watanabe, which has increased plasma levels of LDL and triglycerides (Kita et al. 1981). In 
addition, diabetic animal models have also been developed due to the growing evidence 
that atherosclerosis develops more rapidly with diabetes. Type I diabetes can be induced in 
mice, rats and rabbits by chemically destroying pancreatic β-cells, which leads to 
hyperglycemia due to the hypoinsulinemia. Type 2 diabetes (hyperinsulinemia and 
hyperglycemia due to insulin resistance) models are usually genetically modified mice with 
e.g. leptin receptor deficiency (db/db), and there are some studies with diet-induced type 2 
like changes noted in the atherosclerosis mouse models (Wu and Huan 2007). 
Even with high plasma levels of lipids and the presence of atherosclerotic plaques these 
animal models rarely develop spontaneous occlusions in peripheral arteries. For that reason 
surgical methods to mimic this critical event have been developed. This is especially 
needed when new treatment methods are evaluated in vivo. Commonly used methods are 
ligation of an artery, excision of an arterial section or induction of occlusion by a thrombotic 
agent. The injection of the therapeutic agent can be done e.g. to the ischemic muscle to 
promote an increase in the perfusion of that area. These methods have been used in variety 
of animal models including mice (Couffinhal et al. 1998), rats (Taniyama et al. 2001), rabbits 
(Rissanen et al. 2003; Tsurumi et al. 1996), pigs (Buschmann et al. 2003) and non-human 
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primates (Nakada et al. 2004). The limitation of these models is that the occlusion of the 
artery causes an acute rather than chronic ischemia and the endothelial function is not 
impaired in otherwise healthy animals (Dragneva, Korpisalo, and Ylä-Herttuala 2013). 
 
2.3.2 Fetal growth restriction and reproductive toxicology 
 
Development of the animal models to study fetal growth restriction was started already in 
the 1970’s. The early models included the induction of FGR by exposing the pregnant sheep 
to heat stress. By the early 2000’s the most common models used for FGR research were 
rodents, which covered 75% of the published studies. Larger animal models such as sheep 
and pigs were used in 16% and rabbits and guinea pigs in 9% of the studies. In addition, 
some published data exists also of primates and horses (Medline83 search by Schröder 
[2003]). There are various methods to restrict fetal growth in experimental animals. 
Maternal food restriction can be used, or uterine artery can be ligated partially or totally. In 
addition, especially with larger animals, catheter mediated embolization of maternal side of 
the placenta and restriction of the umbilical cord blood flow by ligation have been used 
(Schröder 2003).  
However, there are significant differences between species which need be taken into 
consideration when studies of FGR or reproductive toxicology are planned and later 
interpreted. The first and probably the most fundamental issue is the differences between 
the placental structures. The human hemomonochorial (one cell layer between fetal and 
maternal circulation) placenta is composed of a villous structure of the capillaries on the 
fetal side and lacunae type of blood flow on the maternal side. Old world monkeys are the 
only mammals that share the placental structure with humans. And of those, only great 
apes (chimpanzees and gorillas) have been shown to have human like trophoblast invasion 
into the myometrium (Pijnenborg, Vercruysse, and Carter 2011a, 2011b). The placentas of 
rodents (mice, rats and guinea pigs) and rabbits do not have villous structures or lacunae 
but capillaries from both the fetal and maternal sides form a labyrinth where the exchange 
of gases and nutrients occurs (Malassine et al. 2003; Enders and Carter 2004; Fischer et al. 
2012). Sheep, on the other hand, have a placental structure that is a combintion of the 
humans and rodents. Whereas the fetal circulation is composed of villous structures like 
human placenta, the maternal side has a closed circulation since villi are surrounded by 
maternal capillaries, not lacunae (Leiser et al. 1997). In addition, gestational times and 
number of offspring vary significantly between species. Mice, rats and rabbits have relative 
short gestation length (19-20, 21-22 and 31-32 days, respectively) and all have usually more 
than five puppies (Malassine et al. 2003; Fonseca et al. 2012; Quinn 2012). In contrast, 
guinea pigs and sheep have longer gestation length than the former species, 59-72 and 
approximately 150 days, respectively. In addition, the number of offspring is smaller, 2-5 
puppies with guinea pigs and singletons or twins with sheep (Crosby et al. 2005; Gresham 
and Haines 2012). 
2.4 ETHICAL ASPECTS OF GENE TRANSFER THERAPY 
There are some issues that need ethical evaluation in gene therapy, especially due to the 
deaths of three participated patients (two adults and one child) and the onset of leukemia in 
four cases. The adults died after adenoviral infusion whereas the children took part in the 
studies using retroviruses to correct their congenital immunodeficiency. One major ethical 
issue to consider is to where to draw the line in risk-benefit evaluation, e.g. how close to the 
doses fatal in animal studies is it acceptable to proceed in clinical trials, and to whom this 
decision belongs. It is clear that researchers should have the ethics to scientifically justify 
the doses and inclusion criteria, but as the case of Jesse Gelsinger shows, bias may occur 
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either due to financial reasons or due to personal ambition. Jesse Gelsinger was the first 
person who died in a gene therapy trial on September 17th 1999. He was not provided with 
all the essential data from animal studies (such as the death of animals), the treatment 
solution was injected even when his serum ammonia levels were out of the study protocol, 
and that one of the principal investigators had substantial financial interests included 
(Wilson 2010). For this reason ethical committees are in place to evaluate the study 
protocols. It is also recommended, at least in the studies where pediatric patients are to be 
treated, either before or after birth, that a bioethical section is included in the study 
protocols preceding clinical trial. Another consideration is whether people competent to 
decide for themselves should be allowed to have more freedom to participate in trials that 
are not yet approved, are on hold or did not fully achieve the efficacy anticipated (EMA 
2001; Edwards et al. 2004; Ginn and Alexander 2012). 
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3 Aims of the study 
The aims of the study were: 
 
I To study whether gamma secretase inhibitor Compound X could be used to 
enhance VEGF-A driven angiogenesis in vivo. 
 
II To test if the modifications made in a baculovirus vector enhance the efficacy of 
the transgene expression in vitro, and whether the putative improvement is 
translatable in vivo, to a model of therapeutic angiogenesis. 
 
III To develop an animal model for reproductive toxicology and to make a 
preliminary assessment whether adenoviruses could be used safely in pregnant 
animals, in order to treat fetal growth restriction. 
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4 Materials and methods 
4.1 VECTOR PRODUCTION AND TESTING 
4.1.1 Adenoviruses (I, III) 
 
Adenoviruses used in this study were clinical grade human vectors containing HSV-TK-
cDNA (Sandmair et al. 2000), human VEGF-A165 cDNA (Mäkinen et al. 2002) or a nuclear 
targeted LacZ cDNA (Laitinen et al. 1997) under the control of a cytomegalovirus promoter. 
The replication deficient adenoviruses (Ad5 serotype; E1 and partial E3 deletion) were 
produced in HEK-293 cells and concentrated by ultracentrifugation. The viruses were 
characterized for titer, potency assays, E1/E2 selective PCR and cytopathic effect on A549 
cells. In addition, viral analysis showed the samples to be free from microbiological 
contaminants, mycoplasma and endotoxins. 
4.1.2 Baculoviruses (II) 
 
Recombinant baculoviral genomes were prepared using the BVboost system (Airenne et al. 
2003) and recombinant viruses were amplified in Sf9 insect cells. The cells were cultured at 
27 °C in serum free BioWhittaker’s Insect-Xpress –medium (Lonza) without antibiotics. Sf9 
cell culture, high-titer virus production and assessment of virus titer were done using 
standard methods (Airenne et al. 2011). To study the effect of woodchuck hepatitis post-
transcriptional regulatory element (WPRE) in the expression cassette and vesicular 
stomatitis virus G protein (VSV-G) on the envelope four different plasmids, pBVboostFGII, 
pBVboostFGII+Wpre, pBVboostFGII+VSV-G and pBVboostFGII+Wpre-VSV-G (Laitinen et 
al. 2005; Mähönen et al. 2007), were used to produce both the reporter gene (LacZ) and the 
therapeutic gene (VEGF-DΔNΔC) containing vectors. All virus preparations were tested for 
sterility and functionality (luminescent b-galactosidase enzyme assay [Clontech, BD 
Biosciences] and human VEGF-D-specific enzyme-linked immunosorbent assay [ELISA; 
R&D Systems] for LacZ and VEGF-D expressing vectors, respectively) in vitro before 
conducting animal experiments. 
4.2 IN VITRO TESTING OF GSI (I) 
Human umbilical vein endothelial cells (HUVECs, PromoCell) were cultured according to 
the manufacturer’s instructions. HUVECs clustered into spheroids in cell culture media 
overnight and were dispensed into a 3-dimensional collagen type I matrix (Korff and 
Augustin 1999). Spheroids were assayed for sprouting in the presence of different 
concentrations of GSI (Compound X, CX, synthetized as described in Searfoss et al. [2003]) 
for 24 h and the ten longest sprouts from ten spheroids were summarized as cumulative 
sprout length. 
4.3 ANIMAL MODELS (I-III) 
Healthy New Zealand White (NZW) female rabbits were purchased from commercial 
suppliers (HB Lidköpings kaninfarm [I, II, III], Harlan [II, unpublished work] or Charles 
River laboratories [unpublished work]). BALB/c, NMRI and C57bl6J mice were purchased 
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from Taconic (I). All animal experiments were authorized by the Experimental Animal 
Committee of Kuopio University until the end of 2005 and thereafter by the National 
Experimental Animal Board in Finland (I – III), in addition by Animal Ethics Committee, 
Göteborg in Sweden (I) and by Ethics Committee for Animal Experimentation according to 
the United Kingdom Coordinating Committee on Cancer Research Guidelines for the 
RENCA study performed in Germany (I). Animals were housed according to the national 
and international laws and guidelines. For each operation animals were anesthetized and 
post-operative analgesia was provided. In the end of study animals were euthanized under 
deep anesthesia with intra venous (i.v.) injection of saturated magnesium sulphate. 
4.3.1 Mouse models for GSI testing (I) 
 
Two different mouse models were used to test the effect of CX on the vasculature: Neonatal 
retina model (in-house crossing of NMRI and C57bl6J; Hellström et al. 2007) and renal 
cortical adenocarcinoma (RENCA) tumor model (BALB/c; Salup and Wiltrout 1986). Prior 
to animal experiments the effect of CX on RENCA cell viability at escalating doses was 
assessed in vitro, and it was found that there was no significant effect even at the highest 
dose (10 µM) tested (data not shown). Briefly, in the retina model CX (0 – 20 mg/kg) was 
given intra peritoneally on post-natal days three and four, animals were euthanized on post 
natal day 5 and retinas were processed and analyzed for vascular changes. In the tumor 
model 4x105 RENCA cells (ATCC) in 25 µl volume were inoculated into the subcapsular 
space of the left kidney through flank incision of each mouse under isoflurane anesthesia 
(1.5 – 2% isoflurane/2 L/min oxygen). Animals were treated with CX (0 or 10 mg/kg) for 
twenty days followed by euthanasia, tumor processing and analysis.  
4.3.2 Rabbit model for skeletal muscle gene transfer (I, II) 
 
Gene transfers were performed in the semimembranosus thigh muscle with 25 Gauge needle 
by injecting 10 x 100 µl (adenovirus, I) or 10 x 50 µl (baculovirus, II) vector solution or 
buffer (I and II; Rissanen et al. 2005). Contrast enhanced ultrasound analysis was performed 
according to Rissanen and co-workers to evaluate the changes in the perfusion in the target 
muscle (Rissanen et al. 2008). Both gene transfers and ultrasound analyses were done under 
anesthesia (medetomidine 0,3 mg/kg and ketamine 20 mg/kg). CX or buffer was given daily 
subcutaneously (sc.; I). Animals were euthanized on day six after the gene transfer since 
adenoviral expression peaks approximately at that time (Vajanto et al. 2002). For modified 
the Miles assay, Evans Blue (30 mg/kg) was given i.v. 30 minutes prior to euthanasia and 
animals were perfused with 1% paraformaldehyde (PFA) in 0.05 M citric acid, pH 3.5. 
Samples were collected for histology, ELISA analysis and modified Miles assay. 
4.3.3 Rabbit model for reproductive toxicity testing (III, unpublished work) 
 
The rabbit model used in this thesis was adopted from a previous study performed by 
Heikkilä et al. (2001) and further developed to meet the criteria for Good Laboratory 
Practice (GLP) quality reproductive toxicology study. At first rabbits were anesthetized 
with ketamine (10 mg/kg i.m. and i.v.) and promazinum hydrochloridium (0.5 mg/kg i.m. 
and i.v.) followed by halothane inhalation. Anesthesia protocol was further optimized and 
the final anesthesia protocol included pre-operative antibiotic (oxytetracycline 15 mg/kg) 
and analgesic (meloxicam 0.2 mg/kg), anesthetics (midazolam 0.4 mg/kg i.m., butorfanol 0.4 
mg/kg i.m. and ketamine 5 mg/kg i.m.) followed by isoflurane inhalation (2%/4 L/min 
oxygen). Local analgesic (lidocain 20-80 mg/kg) was applied on the incision sites and 
buprofein (0.05 mg/kg) was given after the operation. In addition, antibiotic 
(oxytetracycline 15 mg/kg) and analgesic (meloxicam 0.1 mg/kg) was given on the three 
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proceeding post-operative days. All medicines were given subcutaneously unless otherwise 
stated. 
Vascular access was made by placing a 4F introducer in the right carotid artery through 
which a 4F diagnostic catheter was navigated to the abdominal aorta right proximal to its 
bifurcation. An angiogram was obtained to visualize both iliac arteries and branching 
uterine arteries. A 2F injection catheter was then navigated to the uterine artery and 0.5 – 2 
ml of adenovirus or buffer were injected (III). 
To further develop the model to meet the anticipated pre-clinical toxicology and clinical 
trials, a proportion of animals were subjected to a laparotomy where a manual occlusion of 
the uterine artery was performed for the time of injection (Figure 7). Injected solution was 
allowed to stand in the artery for 2 minutes before removing the catheter and restoring the 
blood flow. The injection was then repeated on the other side. In addition, a number of 
injection catheters with inflatable balloon were tested. Animals were culled ten days after 
injections (gestation day [GD] 29). There were five doe that were left to give birth to 
measure whether the gene transfer affected birth weight or neonatal survival. The number 
of surviving fetuses was recorded. Uterine artery, distal, middle and proximal placentas, 
umbilical cords and fetal livers from both sides where available, as well as doe liver were 
collected for histological and PCR analyses. Histological samples were fixed in 4% PFA in 
7.5% sucrose for four hours, then placed in 15% sucrose and processed into paraffin blocks 
within two weeks. PCR samples were snap frozen in liquid nitrogen and stored at -70°C. 
Emphasis was put on the evaluation of the trans-placental diffusion of the vector from 
maternal circulation to the fetus (III) and on the optimization of the surgical operation and 
anesthesia to maximize the fetal survival. 
 
Figure 7. Angiography images to show the position of the injection catheter in the left uterine 
artery for the laparotomy operation. Black arrow in the left panel indicates the origin of the left 
uterine artery branching from the internal iliac artery. Red arrow and arrowhead in the right 
panel show the tip of the injection catheter and the guide wire, respectively. 
4.4 ENZYME LINKED IMMUNOSORBENT ASSAY (II) 
A commercial ELISA was used to detect the human VEGF-D from the tissue samples 
(Quantikine, R&D Systems). For the analysis tissues (injected and intact muscles [m. 
semimembranosus and m. rectus, respectively], lung, heart, liver, spleen, kidney and ovary) 
and serum were harvested at the autopsy, snap frozen in liquid nitrogen and stored in -70 
°C freezer. For the protein quantification tissues were thawed and proteins were extracted 
with buffer (pH 7.2) containing 2.5M NaCl, 15mM phosphate, 0.2% NP-40, 10% glycerol 
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and complete protease inhibitors (Boehringer). The amount of total protein in muscle 
samples was measured with Uptima BC Assay (Interchim). The same human VEGF-D 
ELISA was used for tissue samples as was used for cell culture samples. VEGF-D result 
from the muscle sample was normalized to the amount of total protein measured from the 
same sample. 
4.5 HISTOLOGY (I-III, UNPUBLISHED WORK) 
For the histological analysis tissue samples were fixed in the 4% PFA in 7.5 % sucrose, pH 
7.4 for 4 h and stored in 15% sucrose up to two weeks until processed into paraffin blocks. 
Blocks were cut into 4 µm sections, deparaffinized with xylene and rehydrated through an 
alcohol series. For the analysis of capillary changes due to the CX treatment and/or VEGF 
gene transfer a panel of antibodies were used to detect endothelium (isolectin B4, PECAM-
1, CD31, podocalyxing) and smooth muscle cell actin (αSMA-Cy3). To analyze transfection 
efficacy after LacZ gene transfer, tissues were X-gal stained (III) or immunohistochemically 
stained with antibody against and β-galactosidase (II). In addition, to analyze the basic 
histological changes and apoptosis in tissues, hematoxylin-eosin staining (I – III) and 
apoptosis staining (I, III) were performed. Micrographs were taken with an Olympus AX70 
microscope (Olympus Optical; I – III) or ZEISS AxioImager.M2 (Zeiss; I) and images were 
analyzed using analySIS imaging software (Soft Imaging System). 
4.6 RT-PCR, PCR AND QPCR (III, UNPUBLISHED WORK) 
To analyze the transgene expression in different tissues after AdTK and AdLacZ gene 
transfers, DNA or RNA was isolated with Trizol reagent (Invitrogen) and 3 µg of total RNA 
were used for cDNA synthesis. Two PCRs, PCR I and PCR II, from two areas of each 
transgene were repeated in triplicate for each sample (nested PCR). For PCR I the forward 
primers were located in the promoter region and the reverse primers in the coding region 
of the individual transgene. The primers were 5’-AAA TGG GCGGTA GGC GTG TA-3’ and 
5’-AGG CGG TGT TGTGTG GTG TA-3’ for TK-PCR I, and 5’-TTG GAG GCC TAG GCT 
TTT GC-3’ and 5’-TGA GGG GAC GAC GAC AGT AT-3’ for LacZ-PCR I. For PCR II, the 
both primers were located in the coding region of each transgene; 5’-AGA AAA TGC CCA 
CGC TAC TG-3’ and 5’-GTT ATC TGG GCG CTT GTC AT-3’ for TK-PCR II and 5’-ACT 
ATC CCG ACC GCC TTA CT-3’ and 5’-CTG TAG CGG CTG ATG TTG AA-3’ for LacZ. 
The lengths of the amplified fragments were 483 bp in TK-PCR I, 250 bp in TK-PCR II, 384 
bp in LacZ-PCR I and 175 bp in LacZ-PCR II. AdTK primers were used also with samples 
from AdLacZ treated animals and vice versa to verify the specificity (III).  
To analyze the transduced VEGF-DΔNΔC gene expression after uterine artery gene 
transfers snap frozen samples were homogenized with 500 µl TRISure™ (Bioline) and 
Precellys ceramic beads (03961CK14, Bertin Technologies) using the Precellys 24 bead 
grinder equipment (5000 rpm, 2 x 10 s, 10 s break). The homogenate (500 µl) was 
transferred to a fresh tube containing 500 µl TRISure™ and vortexed. The following 
modifications were made to the manufacturer’s instructions when RNA was isolated: 
centrifugation step after adding isopropyl alcohol was prolonged to 15 minutes and the 
isolated RNA was dissolved in sterile water containing ribonuclease inhibitor (1 U/µl, 
RiboLock™, Fermentas). 
RNA samples were DNase treated and cDNA synthesis was carried out with random 
hexamer primers (#C1181, Promega), 5 x reaction buffer (#M531A, Promega), dNTPs 
(#U1240, Promega), ribonuclease inhibitor (#E00382, Fermentas), sterile water and M-MLV 
reverse transcriptase (#M3682, Promega). 
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Standard curve was generated from a plasmid standard (pBVboostFGII-VEGFΔNΔC, size 
8100 bp) ranging from 10-4 to 10-8 ng (i.e. 1x104 - 1 copies of target sequence). For analysis of 
transgene, expression of the target gene in each experimental sample was quantitated by 
extrapolation from the plasmid standard. The quantitative real time PCR was performed 
using the 7500 Real-Time PCR System (Applied Biosystems) with the following primers 
and probe: Fw-VEGF-D (TCTTCCACCTGGGACTCCAA), Rev-VEGF-D 
(CACTGAGTTCTTTGCCATTCTTCAT), Probe-VEGF-D (FAM-MGB) 
(TGACATTGAAACACTAAAAG). As an internal control 18S ribosomal RNA (rRNA) was 
used for quantitative RNA analysis and as such the second set of PCR reactions were 
performed for the experimental samples using Ribosomal RNA control reagents (#4308329, 
Applied Biosystems). Relative values for rRNA abundance in each experimental sample 
was extrapolated from the standard curve generated from one of the experimental samples 
used as a reference sample (1 ng, 0.1 ng, 0.01 ng, 0.001ng, 0.0001 ng of RNA converted to 
cDNA). For the comparison of different samples VEGF-DΔNΔC mRNA copy numbers were 
normalized to 18S rRNA levels. 
4.7 SOUTHERN BLOTTING (III) 
To analyze trans-placental vector diffusion 483 bp TK and 384 bp LacZ probes were 
amplified from corresponding plasmids using the same primers as with TK-PCR I and 
LacZ-PCR I. TK or LacZ probes (50 ng) were labeled with [32P]dCTP using Ready-To-Go 
DNA labeling Beads (Amersham Biosciences) and purified using ProbeQuant G-50 Micro 
Column according to the manufacturer’s instructions. Digested genomic DNA (5 – 10 µg) 
was run on agarose gels and transferred to Hybond N+ Nylon Filter (Amersham 
Biosciences). The filter was pre-hybridized for 1 h at 68°C with ExpressHyb Solution 
(Clontech) containing 0.1 mg/ml denatured salmon sperm DNA (Sigma). Hybridization 
was performed overnight at 68°C followed by multiple washing steps according to 
ExpressHyb Hybrization Solution User Manual. The film was developed after 3-days 
exposure to X-ray film at −70°C. 
4.8 STATISTICAL ANALYSES (I-II) 
Student’s t-test was performed for comparison of two groups and ANOVA followed by 
Tukey's multiple comparison test were performed for analysis of three or more groups. The 
t-test was calculated as unpaired and two-tailed, except for the analysis of αSMA-coated 
vessels that was calculated for one-sided. The Chi-square test was used when analyzing the 
frequency of occluded vessels (I). The GraphPad Prism software was used for all statistical 
analysis and p<0.05 was considered statistically significant. 
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5 Results and discussion 
5.1 EFFECT AND SAFETY OF COMPOUND X (I) 
Previous studies have shown potent γ-secretase activity and Notch signaling inhibition in 
vitro and in vivo with γ-secretase inhibitors (Searfoss et al. 2003). In this study, we tested 
whether CX directly promotes angiogenic sprouting in vitro, by titrating CX in a cellular 
angiogenesis assay. In the assay, clustered HUVECs form sprouts in a three dimensional 
collagen type I gel. CX induced HUVEC sprouting dose-dependently with an EC50 of 8.8 
mM. In addition, four other compounds pertaining to different classes of GSI inhibitors 
(LY450.139, Sulfonamide 565763, WPE-III-31C and DAPT) were tested to verify that GSI 
inhibitors affect angiogenesis similarly. All compounds promoted angiogenic sprouting 
dose-dependently. It has also been shown that genetic or pharmacological inhibition of 
Notch signaling leads to increased angiogenic sprouting in vivo during developmental 
angiogenesis of the retina (Hellström et al. 2007). In this study, it was also observed that CX 
dose-dependently increased the vascular density of the early postnatal retina at doses from 
5 to 20 mg/kg/day. Treatment with CX between postnatal day (P) 3 and 5 led to increased 
vascular density in the outermost two thirds of the retina, which was accompanied by a 
large number of endothelial tip cells at the sprouting vascular front at the periphery (Figure 
8 A – D). In line with this, treatment with CX (10 mg/kg) between P3 and P5 led to a 68% 
increase in the number of endothelial filopodial protrusions at the vascular front, compared 
to control. Thus, the pattern of vascular formation after CX treatment was essentially 
morphologically indistinguishable from treatment with other GSIs such as DAPT. 
To assess the effect of Compound X treatment on tumor growth and vessel formation in 
the tumor setting, mice were treated with CX (0 or 10 mg/kg/day) in a model of renal cell 
carcinoma. The CX dose used in the study did affect the angiogenic sprouting but not the 
cell viability. In the RENCA tumor model, vehicle-treated animals lost weight over time 
due to the tumor burden; this reduction at day 20 was 5.5% of the initial weight. In contrast, 
CX-treated animals did not show a significant weight reduction. At the end of the study, 
the primary tumor volume and wet weight were both reduced after CX treatment; 53% and 
38%, respectively, compared to controls. The microvascular density (MVD) in CX treated 
animals was increased by 29% compared to controls. In addition, the blood vessel 
morphology was altered. The vessel perimeter surrounding the CD31 positive structures in 
the CX-treated group was increased by 33% compared to control. However, it appeared as 
if several blood vessels were in the process of merging into larger blood vessel structures 
rather than dilating (Figure 8 E, F). Endothelial cells appeared different in CX treated 
tumors compared to controls. After CX treatment the endothelial surface was uneven and 
the number of filopodia-like protrusions from endothelial cells was increased more than 
two-fold as compared to controls. The mural cell coverage of the tumor vasculature was 
quantified as percentage of CD31 positive blood vessels that were associated with α-
smooth muscle actin (αSMA) positive cells. In the vehicle treated group the number of 
αSMA positive blood vessels was small (16%) and most of these were only partially 
covered. The mural cell coverage was reduced by 61% in the CX treated group compared to 
controls. Interestingly, we also observed a higher frequency of vessels filled with a CD31 
positive content. In trying to differentiate such vessels from the ones having merely been 
tangentially sectioned, we quantified only large vessels with CD31 positive content as being 
‘‘occluded vessels’’. Occluded vessels were seen in proximity to areas undergoing necrosis 
and were 2-fold more common in the CX treated tumors compared to vehicle control. 
Moreover, the intraluminal occlusions were positive for the endothelial markers CD31 and 
podocalyxin, as well as the nuclear stain DAPI, suggesting that they are viable endothelial 
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cells and not membranous or matrix material. However, there were no differences in 
proliferation (BrdU-incorporation), apoptosis (TUNEL and cleaved Caspase 3 stainings), 
and area of necrosis, although significant changes in MVD and tumor size between vehicle 
and CX-treated animals were observed (data not shown). 
 
Figure 8. Effect of CX after systemic administration in vivo. In the neonatal mouse retina CX 
dose dependently increased the vascular density and sprouting (A – D). The same phenomenon 
was detected in the mouse RENCA tumor model (E and F). In the rabbit model the effect of CX 
in combination with i.m. AdVEGF-A injection was detected in liver (G – I) as increasing 
sinusoidal staining and biliary duct occlusion. In addition, in the target semimbranous muscle (J 
– M) intraluminal structures of endothelial origin appeared in the blood vessels. Scale bar 100 
µm in A – F, 200 µm in G – M. 
 
To study the effect of CX on vascular morphogenesis and functionality in a relevant, yet 
less complex milieu than that of a tumor, rabbit hindlimb model was used. In this model, 
adenoviral VEGF-A165 gene transfer to the semimembranous muscle led to vessel dilation 
and endothelial cell proliferation not seen in skeletal muscle transduced with adenovirus 
encoding a control gene, LacZ. Contrast pulse sequence (CPS) ultrasound was used to 
determine the perfusion in live animals. In this study, VEGF-A165 gene transfer resulted in 
greater than 10-fold increase of vascular perfusion compared to the control leg. To evaluate 
the safety of the CX dose to be administered, several clinical-chemistry markers were 
analyzed. Even at low doses (1 – 2 mg/kg) liver toxicity was evident, as there was a dose-
dependent increase in serum total bilirubin, serum alkaline phosphatase and serum alanin 
aminotransferase. In addition, an increase in the level of serum creatinin was observed, 
indicating kidney damage. Histological analysis of the liver using CD31 staining revealed 
dose-dependent, severe dilation of the sinusoids upon CX treatment, as well as increased 
staining intensity of CD31. Furthermore, intrahepatic bile ducts were occluded by epithelial 
structures, a finding in line with the increased s-ALP (Figure 8 G – I). In comparison to only 
AdVEGF-A treated skeletal muscle, the additional administration of CX resulted in dose-
dependent blood vessel dilation, and most notably an increased number of CD31 positive 
structures filling the lumen of the vessels (Figure 8 J – M). Staining for another endothelial 
marker, podocalyxin, verified the intraluminal structures as endothelial cells. In addition, 
CX treatment induced a dose-dependent decrease in vascular perfusion, measured as a 
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reduced CPS signal. Doses of 1 or 2 mg/kg/day of CX reduced blood flow by 48% and 66% 
compared to controls, respectively. Furthermore, CX induced an increase in blood vessel 
leakage, which was determined using the modified Miles assay. Adenoviral gene transfer 
of VEGF-A alone resulted in a 35-fold increase of Evans blue leakage and when combined 
with CX treatment (2 mg/kg/day) the result was a 76-fold increase in the leakage of the 
newly formed vessels. Importantly, there were no differences in permeability between 
vehicle-treated and CX-treated muscles in the absence of AdVEGF-A gene transfer. 
Taken together, GSI treatment seems to lead to endothelial hyper-proliferation and 
consequently occlusion of newly formed blood vessels. This further leads to reduced 
vascular perfusion and increased vascular permeability. In addition, CX treatment resulted 
in significant liver and kidney toxicity, partly due to the abnormal activation of the 
endothelial cells, and specifically in the case of hepatotoxicity, due to the occluded bile 
ducts. It was evident after the rabbit study that CX, and probably GSIs in general, have 
such a universal role in the cell fate determination, that it is not useful for therapeutic 
angiogenesis. However, there may be a role for CX in cancer therapy where a disruption of 
angiogenesis is a favorable effect. If such an approach would be taken, then pre-clinical 
studies need to be carefully designed before conducting clinical trials. 
5.2 EFFICACY AND SAFETY OF THE BACULOVIRAL GENE TRANSFER (II) 
To examine the use of baculoviruses as vectors to induce transgene expression, in 
comparison to adenoviruses, both in vitro and in vivo methods were used. It was evident in 
cell culture assays that adding additional elements to the baculoviral vector significantly 
increased the efficacy. BVboost based production of FGII vector combined with both WPRE 
in the expression cassette and VSV-G in the virus envelope increased the efficacy in 293T, 
HepG2 and RaaSMC cell lines when LacZ was used as a transgene. The result was further 
confirmed in RaaSMC cell line using VEGF-D∆N∆C as a transgene. 
The visual inspection of LacZ transduced cells after X-gal staining showed a remarkable 
increase in the number of cells expressing the transgene, in all cell lines tested, when both 
of the elements were added to the vector. In RaaSMC cells, with a MOI of 1000, the 
proportion of positive cells was less than 1 % with the vector without WPRE and VSV-G, 
whereas over 90 % of cells were positive after transduction with a vector carrying both of 
these sequences. Likewise, WPRE and VSV-G in baculoviral vector improved the 
transduction efficiency from 30% to 85% in HepG2 cells, and from 20% to 80% in 293T cells. 
When the efficacy was tested at the level of protein production of the transgene in the 
transduced cells, the results were well in-line with increased efficacy in transduction. 
Following baculoviral transduction with MOI of 1000, the β-galactosidase activity, as 
measured with a luminescent assay, was significantly increased. Additional tests were 
conducted on RaaSMC cells using vectors carrying VEGF-D∆N∆C as the transgene. Protein 
amounts were measured by commercial ELISA assay which recognizes human VEGF-D 
protein. The vector which also included both WPRE and VSV-G, was able to produce 
approximately 10-fold higher amount of VEGF-D compared to the vector without these 
elements, at MOI of 1000. 
Encouraged by these results, a set of in vivo tests was carried out. A rabbit hindlimb 
model was chosen due to its relative large size compared to the mice and because it has 
been widely used when angiogenic compounds have been tested (Rissanen et al. 2003). 
First, the tolerance test was performed to find out whether there is a limit on the dose of 
baculovirus that can be administered. If the dose was 5x109 pfu or more skeletal muscle 
cells started to die at the injection site which was seen as loss of nuclei and reduced 
cytoplasmic staining. However, no adverse effects were seen in other tissues or in the 
overall welfare of the rabbits. It was determined that the dose that could be administered to 
the rabbit semimembranosus muscle without inducing major necrosis was limited to 109 
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pfu aliquoted in ten 50 µl injections. Even with this dose a significant increase in capillary 
size was reached with BVboostFG+VEGF-DΔNΔC vector. However, the dose is approximately 
100 times less than the tolerated dose of adenovirus and the capillary enlargement was 
more modest than that achieved with the adenoviruses. In addition, when the most efficient 
(in vitro) baculoviral vector, pBVboostFGII+Wpre-VSV-G-VEGF-D∆N∆C, was used in the 
rabbit model, no statistical significance in the capillary enlargement was achieved even 
when the enlargement of many capillaries was substantial. This was most likely due to the 
fact that although there were capillaries that were clearly more enlarged than those of a 
previous study, these were scattered and fewer in number, which resulted in relatively 
large standard deviation (Figure 9). 
 
Figure 9. Addition of WPRE and VSV-G to the baculovirus vector expressing VEGF-D∆N∆C clearly 
increased capillary size in the target muscles (arrow). Capillary enlargement was not seen with 
vectors carrying LacZ with or without these elements. (a) BVboostFGII-LacZ, (b) 
BVboostFGII+Wpre-VSV-G-LacZ, (c) BVboostFGII-VEGF-D∆N∆C, (d) BVboostFGII+Wpre-VSV-G-
VEGF-D∆N∆C. Scale bar 200 µm, magnification 200x. 
 
To conclude, the insect cell originating envelope of the baculovirus vector and/or the 
impurities from the vector production in the insect cell culture, seem to induce severe 
immune reaction in rabbit skeletal muscle which reduces the number of vector particles 
that can be injected into the muscle tissue leading to modest gene transfer efficiency. This 
may be resolved by improving the vector purification methods and protecting the vector 
from complement activation. Promising results of the latter have already been obtained 
(Kaikkonen et al. 2010). In addition, a complex of baculovirus and Tat/DNA nanoparticles 
has been show to improve gene transfer efficacy in rat myocardial infarction model (Paul et 
33 
 
 
al. 2011). These improvements may enhance the efficacy of baculovirus mediated gene 
transfers also in the immune competent tissues. However, in the area of angiogenic gene 
therapy transient transgene expression, lasting less than two weeks, may not be sufficient. 
One alternative in the field of viral gene therapy is the use of integrating vectors but this 
approach also has its limits. The other option could be a combination of two different 
vectors with transient expression, administrated sequentially, to gain longer lasting 
expression but avoiding the problems of integrating vectors. 
5.3 ANIMAL MODEL FOR REPRODUCTIVE TOXICOLOGY (III, 
UNPUBLISHED DATA) 
In the first study, the effects of gene transfer on the fertility and germline transition were 
investigated after uterine arterial gene transfer with adenovirus on GD14. In addition, the 
presence of the transgene and/or the vector in the fetus was investigated. In the second 
study, both anesthesia and operation protocol were optimized to maximize the fetal 
survival. The transgene expression in the fetus livers was studied as well. The litter size 
was significantly lower in the operated animals compared to the litter size of the untreated 
colony. However, when the operated animals were mated later the litter size did not differ 
from the litter size of the colony. This indicates that adenoviral gene transfer do not have 
long term effects on the fertility. The reason for the reduced litter size after the operation 
remains unsolved but the stress due to the anesthesia and the surgical procedure appear to 
be more probable reasons for this, than adenovirus or transgene expression. This is 
supported by the fact that in the second study the viral dose remained the same throughout 
the study and the fetal survival improved as the anesthesia and operation protocol were 
altered. 
The results of the first study suggested that adenovirus or the transgene is able to pass 
through the placenta to the fetus. In addition, the vector or the transgene were able to 
remain in the mother and to transfer to the next generation, probably in the oocytes or in 
the myometrium, up to 4 months after the gene transer since there were some fetal liver 
samples of the second litter in which the transgene was detected with PCR. However, no 
detectable transgene was observed in any other fetal organ and southern blot analysis did 
not show any transgene presence in any fetal organs. Furthermore, no transgene expression 
was detected in the total RNA (Figure 10) or at the protein level (Figure 11) from the fetal 
liver samples obtained from the unpublished study. These results indicate that the 
transmission detected was blood borne, that is, transferred to the fetal liver from the 
maternal side during placental development. 
The last part of the animal model development was the optimization of the anesthesia 
protocol and adapting the proposed clinical delivery time and method. In the anesthesia 
protocol the harmful halothane was replaced with more less toxic isoflurane. The second 
step was to look for the sedatives with minimum hypoxic impact. The final combination 
was found to be well tolerated with no difference in the litter size or the fetal survival 
compared to the respective numbers of the non-operated breeding colony. The time of gene 
transfer was postponed from GD14 to GD19 to mimic the end of the second trimester in 
humans. The injection of the vector in the clinic is intended to be performed with the 
catheter that has an inflatable balloon to halt the blood flow. Thus, several balloon catheters 
were tested in the rabbit model. However, even the most flexible ones that were able to 
bend to the uterine artery were too large to be inflated safely in the artery. There were clear 
indications of arterial disruptions and lack of sufficient blood flow to the placentas noted at 
autopsy 10 days after the operation. The fetal loss was high and hemorrhages were noted at 
the sites where the balloons were inflated. With the available methods, it was not possible 
to detect whether there was any blood flow passing the plain injection catheter. For this 
reason a laparotomy was performed and any possible blood flow was stopped by pressing 
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the artery around the catheter during the injection. It was noted that there was no 
difference in the fetal survival whether the laparotomy was performed or not. The overall 
fetal survival in both groups was approximately 70%. However, the variation in the fetal 
survival rate was high: from aborting all fetuses a few days after operation to over 90% of 
fetuses surviving. This indicates a large individual variation of animal tolerance to the 
operation itself, thus there were no differences between the injected substances. In addition, 
there was no clear correlation between the operation time and fetal survival. 
These results indicate that a modified adenovirus injected into the uterine artery during 
the second trimester of the rabbit pregnancy does not result in transgene expression in the 
fetal liver. In addition, results of improved blood flow in a study with pregnant sheep 
(David et al. 2008) suggest that this method could be used as a treatment for FGR, as the 
mortality and morbidity are decreased the bigger the fetus can grow in the uterus. 
However, due to the fact that the ultimate goal of this method is to treat pregnant women 
the full scale GLP reproductive toxicology study is to be performed before entering into the 
clinical trials. In addition, even if the GLP study with rabbits shows no vector or transgene 
presence in the fetal tissues, the difference between human and rabbit placental circulations 
needs to be kept in mind before the final decision of entering into the clinic is made. 
 
Figure 10. Quantitative RT-PCR showed VEGF-D expression in the doe liver, placenta and 
uterine artery after adenoviral gene transfer of VEGF-DΔNΔC. No expression was seen in the fetus 
liver. nd = not detected, the data is presented as the mean ± standard deviation. 
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Figure 11. Immunohistochemical staining for LacZ demonstating transgene expression (brown 
dots) in the placenta (A) but no staining was seen in the fetal liver (B) when 1011 vp in 2.5 ml 
were injected into the uterine artery. In addition, there were positive cells detected in the doe 
liver (C). However, if the dose was reduced to 1010 vp and injection volume to 0.5 ml, no 
positive cells were seen in either the placenta (D) or the doe liver (E). Scale bar 100 µm. 
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6 Conclusions 
I In this study it was found that in rabbit skeletal muscle, the Compound X 
together with the adenoviral mediated VEGF-A165 gene transfer-induced 
angiogenesis, did not lead to increased sprouting of vessels due to increased tip 
cell number, in contrast to the mouse neonatal retina model. In fact, the results 
demonstrated a disruption of the vessel wall integrity and excess CD31 positive 
cells inside the vessel lumens in target muscles. In addition, liver morphology 
was disturbed as there was severe dilation of sinusoids and occlusion of the 
bile ducts by the epithelial cells. Thus, combining CX with AdVEGF-A165 
therapy cannot be considered safe enough to be taken to clinical trials. 
 
II Baculoviruses were shown to be very effective vehicles for gene transfer in 
different cell lines in vitro after the inclusion of WPRE and VSV-G elements in 
the vector. However, this did not directly translate to a better in vivo efficacy. 
The main reason seems to be the limited amount of viral particles that could be 
administered to the rabbit muscles due to stimulation of an immune reaction 
likely by the insect cell derived virus envelope. This limits the safety and thus 
the feasibility of the vector as a potent vehicle for angiogenic therapy with 
patients who have functional immune system. 
 
III The rabbit model was developed for the GLP grade study for testing the 
biodistribution and tolerance of adenoviral VEGF-DΔNΔC gene transfer. The 
anesthesia was optimized and delivery method was developed to mimic the 
proposed clinical method. These preliminary studies indicate that the transgene 
or vector is able to pass through the placenta to the fetus to some extent but that 
the transgene is not expressed in the fetus. The safety of the method is of 
question and must be addressed in the forthcoming GLP study. 
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